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GENERAL INTRODUCTION 
Osteoclasts are the principal bone resorbing cells of the body. 
The bone calcium-mobilizing hormones, parathyroid hormone (PTH) and 
1,25-dihydroxyvitamin Dg (calcitriol), increase osteoclast numbers and 
their bone-resorbing activity (1-4). Monocytes also have been proposed 
to be mediators in the bone degradation process. Monocytes are found 
in areas of bone-resorbing osteoclasts and chronic inflammation (5-8), 
degrade devitalized bone (9), and are chemotactic to areas of resorbing 
bone (10). A particularly significant study reported that administra­
tion of a large dose of calcitriol to a child with osteopetrosis, a 
disease characterized by bone resorption dysfunction, resulted in an 
increase of osteoclast resorption and also an increase in monocyte-
mediated bone degradation (11), thus suggesting calcitriol stimulation 
of both of these two cell types during bone resorption. Heersche (12) 
also proposed that the immediate bone resorption mechanism involves 
both osteoclast bone resorption and a "scavenger-helper" role of 
monocytes to remove and phagocytize bone debris. It is in the context 
of the monocyte as a scavenger cell distinct from the osteoclast bone 
resorption mechanism that I evaluated monocyte-mediated degradation of 
devitalized bone during both PTH and calcitriol administration. 
Additionally, I evaluated production of hydrogen peroxide by monocytes 
during PTH administration as a possible measure of an inflammatory-type 
mechanism for bone degradation activity by monocytes. 
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Calcitriol, in addition to its role in calcium homeostasis, is 
also an immunoregulatory steroid hormone. Recent studies have shown 
that calcitriol induces monocytic differentiation in murine and human 
myeloid leukemia cells (13-16) and that the thymus, monocytes, and 
activated T and B lymphocytes express the calcitriol receptor (17-22). 
The immunoregulatory role of calcitriol is demonstrated further by its 
inhibition of both mitogen-stimulated peripheral blood mononuclear 
cells (PBM) (23, 24) and murine medullary thymocyte proliferation 
(19,25) and its suppression of interleukin (IL-2) production (23, 24). 
In contrast to the antiproliferative effects of calcitriol, Lacey et 
al. (26) reported that calcitriol stimulated the proliferation of a 
nontransformed T-helper cell line in the absence or at low concentra­
tions of interleukin 1 (IL-1). At IL-1 concentrations necessary for 
optimal response, however, addition of calcitriol resulted in inhibi­
tion of proliferation. I sought, therefore, to characterize the in 
vitro response of bovine PBM to several mitogens 1) in the presence of 
calcitriol and 2) after in vivo administration of calcitriol. 
Dissertation Format 
This dissertation is presented in the alternate thesis format, 
which includes two manuscripts. The paper in Section I is coauthored 
by B. J. Nonnecke, D. C. Beitz, R. L. Horst, and T. A. Reinhardt, and 
has been published in Biochemical and Biophysical Research Communica­
tions (Vol. 152: 545-551). The paper in Section II is coauthored by J. 
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P. Goff, B. J. Nonnecke, D. C. Beitz, R. L. Horst, and T. A. Relnhardt 
and is to be submitted to the Journal of Bone and Mineral Research. 
Section III includes research not included in manuscripts for publica­
tion in Sections I and II. A brief review of the literature precedes 
the first manuscript and is concerned principally with firstly the 
scientific basis of monocyte-mediated bone degradation as related to 
the bone calcium-mobilizing hormones PTH and calcltriol, and secondly 
the immunoregulatory role of calcltriol. At the end of each section, a 
separate Literature Cited section has been included. A general Summary 
and Discussion section follows the final manuscript. 
The doctoral candidate, Frank Gerard Edward Hustmyer, was the 
principal Investigator in each of these studies. 
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LITERATURE REVIEW 
Monocyte-Mediated Bone Degradation 
Origin of the osteoclast from blood-borne hematopoietic cells 
The predominant and widely accepted theory on the origin of the 
osteoclast states that osteoclasts are of hematopoietic origin from 
phenotypically similar circulating cells of the monocyte-macrophage 
lineage. The blood-borne origin of osteoclasts initially was sug­
gested by Jordan (27) In 1925 and Hancox (28) in 1949 in which they 
proposed the osteoclast precursor possibly to be a mononuclear wander­
ing cell - either a histiocyte or macrophage. Jee and Nolan (29) 
supported this early hypothesis by demonstrating that phagocytlzed 
charcoal ingested by phagocytes later appeared in osteoclasts. 
Fischman and Hay, utilizing regenerating newt limbs, also suggested a 
mononuclear leukocyte origin for the osteoclast (30). Convincing 
evidence for the hematopoietic origin of osteoclasts, however, was 
provided by a series of experiments in which osteopetrotic animals 
were cured by hematopoietic infusion, parabiosis, and chimeric bone 
grafts. 
Walker demonstrated that the defective osteoclast bone resorption 
that is characteristic of microphthalmic osteopetrotic mice could be 
cured by parabiotic union with normal siblings (31), thus suggesting a 
vascular origin of the cells responsible for rectifying the defect. 
Gbthlln and Ericsson employed parabiotic inbred rats to show the 
hematopoietic origin of osteoclasts. One animal was Irradiated and 
the other was not. Tritlated thymidine-labeled cells from the non-
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irradiated animal were identified later at sites of induced fracture 
in newly formed osteoclasts in the irradiated animal, thus^again 
suggesting a blood-borne origin for the osteoclast (32). 
Transplantation studies in irradiated osteopetrotic mice also 
have been conducted. Irradiated osteopetrotic mouse mutants infused 
with normal bone marrow or spleen cell suspensions were cured of the 
osteopetrotic malady (33, 34), and conversely, irradiated normal 
recipient mice injected with cell suspensions from osteopetrotic 
animals developed the disorder (35). Additionally, Ash et al. (36) 
found that irradiated osteopetrotic microphthalmic (mi/mi) mice 
infused with bone marrow cells with giant lysosomes from beige mice 
(bg/bg) resulted in formation of osteoclasts with giant lysosomes and 
normal bone resorption. Spleen cells from beige mice (bg/bg) that had 
been transplanted into irradiated microphthalmic mice also resulted in 
formation of osteoclasts with giant lysosomes, donor origin, and 
restored normal osteoclast function (37). 
Further evidence for the hematopoietic origin of osteoclasts was 
demonstrated with chick-quail chimeras. Jotereau and LeDouarin (38) 
used the quail nuclei heterochromatin markings to distinguish nuclei 
in the newly formed osteoclast from chick nuclei that do not have 
heterochromatin markings following cross-transplantation of fetal limb 
buds. Chimeric osteoclast formation indicated the hematopoietic 
origin of formed osteoclasts. The heterochromatin markings of quail 
nuclei also were employed in chick-quail chimera experiments in which 
transplanted limb buds were fractured to initiate bone remodeling. 
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The resulting callus formation demonstrated that osteoclasts were of 
host origin, indicating a vascular path for nuclei in newly formed 
osteoclast (39). 
Origin of osteoclast from cells of monocyte-macrophage lineage 
The proposed blood-borne, extraskeletal origin of the osteoclast 
suggested that mononuclear leukocytes may be likely candidates for 
osteoclast precursor cells. The primary focus of investigators has 
been the study of cells of the mononuclear phagocyte system. Jee and 
Nolan (29) and Fischman and Hay (30) suggested a monocyte-macrophage 
origin for the osteoclast, but their studies could not unequivocally 
exclude histiocyte or lymphocyte origin. Several researchers then 
isolated "pure" populations of monocyte-macrophages, labeled these 
populations with an appropriate tag, reintroduced labeled cells into 
animals, and determined whether the marker appeared in developing 
osteoclasts. Stanka and Bargsten (40), Tinker et al. (41), and 
Gathlin and Ericsson (32) prepared labeled (Barr bodies, ^H-thymidine, 
and" Thorotrast, respectively) peripheral blood mononuclear cells at 
several degrees of purity, reintroduced labeled cells into animals, 
and evaluated the newly formed osteoclasts for appropriate label 
content. All studies reported small percentages of labeled osteo­
clasts, but because of discrepancies in purity of originally isolated 
monocyte-macrophage populations and low amount of label in osteoclast, 
no definitive conclusion could be made. 
The ^  vitro fusion of monocyte-macrophage cells with osteoclast-
like cells has been suggested as evidence that circulating monocytes 
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are osteoclast precursor cells. Macrophages in non-skeletal tissues 
fuse into multinucleated giant cells (42) . Zambonin-Zallone et. » 
in a series of photomicrographs and autoradiographic techniques, 
demonstrated fusion of monocytes ^  vitro with prefomned osteoclasts 
(43, 44). One of the difficulties in interpreting the aforementioned 
studies has been based on the impure nature of either the isolated 
mononuclear phagocyte population or the osteoclast bone cultures. Ko 
and Bernard (45) and Burger et al. (46) sought to overcome these 
difficulties by using osteoclast-free fetal mouse bone expiants 
cultured with either 1) nonadherent bone marrow-derived mononuclear 
cells (BMDM) - a highly purified immature mononuclear phagocytes (MNP) 
population, 2) adherent BMDM - a population of more mature MNP, 
fibroblasts, and adipocytes, 3) blood monocytes, or 4) resident and 
exudate peritoneal macrophages. Osteoclast formation was observed 
only in cultures of nonadherent BMDM, and not with adherent BMDM, 
monocytes, or peritoneal macrophages. Ibbotson e^ al. also demon­
strated that osteoclast-like cells formed from nonadherent bone marrow 
monocytic progenitor cells that had been enriched by discontinuous 
Percoll gradient centrifugation (47). Burger e^ al. (48) later 
demonstrated that [^H]-thymidine-labeled nonadherent BMDM, when 
cultured with osteoclast-free bone expiants, resulted in the labeling 
of 88% of nuclei in newly-formed osteoclasts. Exudate peritoneal 
macrophages, however, were inconsistent in ability to form osteo­
clasts, requiring longer culture periods for formation. Observations 
cited in this paragraph suggest that 1) the osteoclast presursor cell 
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is an immature monocyte, possibly a monoblast or promonocyte, and 2) 
that neither the mature tissue macrophage nor the mature blood mono­
cyte will differentiate into osteoclasts. 
The hypothesis that osteoclast development cannot occur via the 
circulating monocytes is strengthened further by several additional 
studies. In an in vivo study, no correlation was evident between the 
kinetics of [^H]-thymidine labeling of monocytes and the subsequent 
detection of labeled DNA of nuclei in osteoclasts (49). Furthermore, 
defective osteoclastic bone resorption evident in osteopetrotic or 
radiation-damaged animals is not corrected by macrophage infusions 
(50, 51). Finally, no evidence has been presented yet of in vitro 
differentiation of peripheral blood monocyte into bona fide osteo­
clasts. These observations strongly suggest that the osteoclast 
progenitor cell is an immature BMDM and that a more differentiated and 
mature monocyte-macrophage is incapable of nascent osteoclast forma­
tion. 
The role of monocyte-mediated bone degradation 
Although monocytes and macrophages do not seem to have the 
capacity for nascent osteoclast formation, these cells secrete prod­
ucts, such as lysosomal enzymes and collagenase (52), that are be­
lieved essential for bone degradation and also degrade devitalized 
bone. Mundy et first reported that blood monocytes degrade 
45 devitalized Ca-labeled bone particles. vitro addition of the 
bone calcium mobilizing hormones, PTH and calcitriol, did not increase 
monocyte-mediated bone degradation (9). Kahn et al. and Rifkin et al. 
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also demonstrated that contact of monocytes with devitalized bone 
particles was required for degradation to occur (53, 54). Resorbing 
bone is also chemotactic for monocytes (10). The degree of bone 
resorption in organ culture induced by PTH, calcitriol, or prosta­
glandin E2, a potent stimulator of osteoclast activity (55), correlated 
with chemotactic activity (10). The bone matrix constituents Type 1 
collagen and OgHS glycoprotein, and osteocalcin, a major noncol-
lagenous protein of bone, all exhibit a dose-dependent chemotactic 
response to monocytes (56-58). This response suggests that these 
substances released during the bone resorption process may provide a 
mechanism for recruitment of monocytes to areas of bone resorption. 
Moreover, the local production of factors, such as interleukin 1 
(IL-1) (59) and prostaglandins (55), stimulate osteoclast bone resorp­
tion, suggesting a monocytic control mechanism for resorption in the 
microenvironment of the bone-resorbing osteoclast. 
Additionally, monocytes may serve an important role in the 
osteolytic process evident at sites of inflammation. Macrophages are 
constituents of inflammatory infiltrates in diseases associated with 
osteolysis, such as periodontitis and rheumatoid arthritis, and are 
associated with osteoclasts during bone resorption (5-8). Induced 
inflammation-mediated osteopenia has been demonstrated in the rat 
(60), and endotoxin treatment of isolated monocytes resulted in 
enhanced ^  vitro monocyte-mediated bone degradation (61). In sum­
mary, studies on monocyte-mediated bone degradation demonstrate that 
monocytes 1) degrade devitalized bone in a contact-mediated mechanism, . 
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2) are possibly recruited to regions of resorbing bone by bone matrix 
constituents, and 3) are found in regions of bone resorption in both 
chronic inflammatory disorders and normal bone resorbing osteoclasts. 
Heersche (12) has proposed a two-cell model for osteoclastic bone 
resorption that is particularly relevant to this summary. The mono­
cyte as proposed by Heersche serves in a "Janitorial-scavenger" role, 
assisting the osteoclast in removal of debris produced during the 
resorption process (12). It is in this context that the monocyte 
shall be examined in this project, i.e., a distinct monocyte-mediated 
bone degradation process accompanying but separate from osteoclastic 
bone resorption. 
Bone remodeling sequence - relation to mononuclear phagocytes 
The proposed role of the monocyte as a separate element in the 
bone resorption process requires an assessment of the possible contri­
bution of this cell type throughout the bone remodeling sequence. 
Frost (62) first hypothesized that bone remodeling involved a sequence 
of cellular events occurring at different remodeling sites along the 
bone surface. The first phase, activation, involved the activation of 
osteoclast precursors and subsequent osteoclast formation. Formed 
osteoclasts then resorbed, during the resorption phase, a portion of 
bone followed by osteoblast differentiation and formation (F phase) of 
new bone at the resorption sites (63). A detailed analysis of this 
hypothesis was conducted later by Tran Van et al. (64, 65) based on 
the induction of a reproducible synchronized remodeling sequence 
during tooth egression in rats. These authors categorized bone 
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remodeling into five phases: 1) activation, 2) resorption, 3) rever­
sal, 4) formation, and 5) resting. 
The bone remodeling sequence seems to proceed in the following 
manner. During the resting phase, the osteoid tissue is covered by a 
uniform layer of active osteoblasts; osteoclasts and mononuclear 
phagocytes usually are absent. The activation phase of bone remodel­
ing is characterized by recruitment, recognition, and attachment of 
osteoclast precursors to specific areas of bone surface (63). Two 
days after induction by extraction of maxillary molars to allow 
mandibular molars to egress, morphology of osteoblast changes to a 
more flattened, elongated shape with reduced cytoplasmic extensions. 
Cells along bone surface are now a heterogeneous mixture of types, 
with cells of mononuclear phagocyte (MNP) characteristics (fluoride-
inhibitable nonspecific esterase-positive cells) in close apposition 
to bone surface and osteoblasts. The MNP contain numerous coated pits 
and pseudopodia in the membrane facing the bone surface. Internaliza­
tion of some bone material seems evident in mononuclear phagocytes, 
and the plasma membrane becomes ruffled. 
When the activation phase ends, the resorption phase begins with 
the fusion of osteoclast precursor cells to form nascent osteoclasts. 
Bone matrix solubilization becomes prominent with mature osteoclasts 
evident over most of bone surfaces. Uncharacteristized mononuclear 
cells of undetermined cell type surround the osteoclast. 
As the resorption phase ends, osteoclasts detach from bone 
surfaces, and the reversal phase begins when large, highly phagocytic 
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mononuclear cells characteristic of mononuclear phagocytes occupy the 
Howship's lacunae created by the osteoclast. At the end of the 
reversal phase, cells with morphological characteristics of preosteo-
blasts and osteoblasts appear in the area previously occupied by the 
phagocytic MNP-like cells and deposit new bone matrix along the 
calcified cement line signaling the beginning of the formation phase. 
Bone matrix formation by osteoblasts continues to replace bone in 
areas resorbed by osteoclasts during the resorption phase (64, 65). 
These studies by Iran Van et al. (64, 65) indicate that cells of the 
mononuclear phagocyte family may play a role in both the activation 
phase during recruitment of osteoclast precursors and/or the reversal 
phase during the increased phagocytic activity of mononuclear cells in 
Howship's lacunae. 
Monocyte-mediated bone degradation in parturient paresis 
In vitro monocyte-mediated bone degradation may be a useful tool 
to study the apparent bone calcium mobilizing defect evident in 
parturient paresis. Parturient paresis (milk fever) is a hypocalcemic 
disorder in dairy cattle evident at the onset of lactation in older, 
high milk-producing cows. The disease is characterized by a coma 
induced by the rapid decline in plasma calcium and phosphorus concen­
trations brought about by the high demand for calcium at onset of milk 
production. Immediate treatment is the infusion of calcium gluconate, 
which sufficiently corrects the malady (66). The etiology of parturi­
ent paresis is unknown. Sufficient concentrations of PTH and cal-
citriol in blood plasma, compared with nonparetic cows, are present at 
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the onset of clinical signs of milk fever. Increases of plasma PTH 
and calcitriol concentrations are not delayed in response to hypocal­
cemia compared to nonparetic controls (67, 68). Calcitonin concentra­
tions are lower in paretic cows than in normal cows, and thus does not 
seem to be a factor in induction of milk fever (69, 70). Evidence 
that sufficient calcitropic hormones are indeed present during onset 
of parturient paresis has lead to the current theory that end organ 
tissues, bone and/or intestine, are resistant to PTH and/or calcitriol 
signals for increased calcium mobilization from bone to blood (71, 
72). 
The theory of end organ resistance as the etiology for parturient 
paresis and evidence that increased bone resorption does not increase 
until 2 to 3 days postpartum (66) suggest that the bone mobilizing 
mechanism is quiescent at peak calcium demand. This prompted the 
development of strategies for prevention of milk fever to be targeted 
at priming the calcium homeostatic mechanisms during the prepartal 
period. Goings ££ £l. (73) demonstrated that parturient paresis could 
be prevented by feeding cows a low calcium diet during the 2-week pre­
partal period. The low calcium dietary regiment stimulated PTH 
secretion, which probably was followed by PTH-stimulated renal produc­
tion of calcitriol and subsequently increased intestinal absorption of 
calcium (73). Goff et al. (74) later reported that prepartal intra­
venous infusions of PTH prevented parturient paresis, thus again 
supporting the efficacy of priming the calcium homeostatic mechanisms 
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to alleviate the apparent end organ resistance to PTH at the onset of 
parturient paresis. 
It is in the context of parturient paresis as a disease charac­
terized by end organ resistance to PTH and calcitriol that we sought 
to characterize the ^  vitro monocyte-mediated bone degradation 
activity of monocytes isolated from paretic and nonparetic cows. A 
similar study was conducted by Key ^  £l. (11) and Glorieux ejt al. 
(75) with patients afflicted with osteopetrosis, which is an end 
organ-resistant disease characterized by deficiencies in bone calcium 
mobilization and resultant sclerotic, dense bone (76). Key et al. 
(11) found that administration of large doses of calcitriol to an 
osteopetrotic child resulted in increased osteoclastic bone resorption 
and also an increase in monocyte-mediated bone degradation. Glorieux 
et al. (75) also demonstrated induction of bone resorption by PTH in 
congenital malignant osteopetrosis. These results, coupled with the 
proposal of Heersche (12) that monocytic bone degradation may be a 
mechanism distinct from osteoclastic bone resorption, prompted me to 
determine whether monocyte-mediated bone degradation is altered during 
the hypocalcemia associated with parturient paresis. 
Bone Calcium Mobilizing Hormones - Effects on Cells 
of Mononuclear Phagocyte Systems 
To understand the role of monocytes in the bone resorption 
process, a brief review of the bone calcium mobilizing hormones, PTH 
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and calcitriol, must be examined. The effects of PTH and calcitriol 
on cells of the mononuclear phagocyte system also will be addressed. 
Vitamin D metabolism and mechanisms of action of metabolites 
Vitamin Dg is derived from either dietary Intake or via photosyn-
thetic (ultraviolet irradiation) conversion of 7-dehydrocholesterol to 
pre-vitamin D3, which, in turn, rapidly Isomerizes to vitamin D3 and 
enters the circulation from the skin (77). Dietary vitamin D3 is 
absorbed by the small Intestine, enters the lymphatic circulation, and 
then enters the bloodstream (78). In the liver, vitamin D3 is hy­
droxy lated by the microsomal enzyme vitamin D3-25-hydroxylase to form 
25-hydroxyvltamin Dg (25-OHD3) (79). 25-OHD3 Is the major circulating 
form of vitamin D and is present in concentrations of 10 to 40 ng/ml 
(10 ^  M) in man (80) and is associated primarily with vitamin D-bind-
ing protein (81). Kidney uptake of 25-OHD3 and further hydroxylatlon 
by the kidney mitochondrial enzyme, 25-hydroxyvltamln D3-la-hydroxylase 
(loi-OHase), results in the formation of 1,25-(0H)2D3 (calcitriol) 
(82). Production of calcitriol is elevated under conditions of 
calcium shortage and decreases under conditions of calcium excess. 
The concentration range of calcitriol in plasma is from 25 to 65 pg/ml 
(10 M). During calcium excess, 25-OHD3 is converted predominantly 
to 24,25-(0H)2D3 (83), a metabolite whose function has yet to be 
established convincingly. Calcitriol is the most active form of 
vitamin D and is the principal mediator of biological effects associ­
ated with vitamin D (84-87). 
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The mechanism of action of calcltrlol is virtually identical to 
that of other steroid hormones (Fig. 1). Calcltrlol circulates bound 
to plasma protein, primarily vitamin D-binding protein. Hormone 
circulating in the free state enters the cell because of its lipo­
philic nature and binds to its intracellular receptor. Formation of 
hormone-receptor complex results in an increased affinity for nuclear 
components relative to that of unoccupied receptor (88, 89). Binding 
of the hormone-receptor complex to specific DNA domains causes repres­
sion or induction of mRNA transcription, specific alterations in 
protein synthesis, and subsequent cell function modulation. Specific 
examples of l,25-(OH)2D3- mediated changes in the synthesis of several 
cell proteins are shown in Fig. 1. 
Effects of calcltrlol on cells of the mononuclear phagocyte system 
Vitamin D deficiencies Urist and McLean (90) first suggested 
a role for vitamin D in hematopoietic cell differentiation by demon­
strating a dramatic increase in number of bone marrow mast cells in 
rats fed a vitamin D-deficient, low calcium diet. Further evidence 
was provided by reports that children with vitamin D-deficient rickets 
often have increased severity and rates of infections (91), and anemia 
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Figure 1. Schematic model of calcltrlol-receptor Interactions and 
the Induction of cellular responses. DBF = vitamin D 
binding protein; S = steroid; R = receptor; CaBP = calcium 
binding protein. 
19 
and extramedullary hematopolesls (92). Isolated monocytes and macro­
phages from ricketic children and mice also have decreased phagocytic 
ability (93, 94). These defects in bone marrow cellularity and 
phagocytosis are improved by vitamin D administration (92, 94, 95). 
Random migration of neutrophils is decreased (96), and capacity of 
neutrophils to phagocytize Escherichia coli also is impaired (41) in 
patients with vitamin D-deficient rickets. An observation related to 
isolated macrophages in vitamin D deficiency was demonstrated by Kahn 
et al. (97): vitro macrophage-mediated bone degradation dysfunc­
tion was observed in isolated macrophages from vitamin D- deficient 
animals, but normalized macrophage-mediated degradation activity was 
evident following administration of calcitriol to mice before cell 
isolation (97). 
Effect of calcitriol on transformed cell lines - myeloid leukemia 
cells Cell growth is decreased and the rate of differentiation to 
monocyte-macrophages is increased in human and murine myeloid leukemia 
cells in the presence of calcitriol as demonstrated in Ml-mouse 
myeloid leukemia cells (13), HL-60-human myeloid leukemia cells 
(promyelocytic) (14-16), U937 cells-human histiocytic lymphoma cells 
(monoblast/histiocytes) (98-100), P388D1 cells-mouse macrophage-like 
lymphoma cells (101), and THP-1 cells-human monoblasts (102). The 
characteristics associated with monocyte-macrophage differentiation 
evaluated in these studies included morphologic changes, increased 
adherence, suppressed proliferation, induced phagocytic activity, Cg 
rosette formation, chemical reduction of nitroblue tetrazolium. 
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increased a-naphthyl acetate esterase activity, expression of specific 
membrane antigens characteristic of cells of monocyte-macrophage 
lineage, and finally the expression of membrane surface antigens, 
including Fc and complement (C3) receptors (13-16, 98-102). Addition­
ally, the acquisition of phenotypic characteristics of monocytes by 
HL-60 cells stimulated by calcitriol is preceded by a marked decrease 
in expression of c-myc oncogene (103). 
The ^  vitro effects of calcitriol on myeloid leukemia cell 
growth and differentiation led Honma et al. (104) to study the effects 
of ^  vivo administration of calcitriol on the leukemogenicity of 
syngeneic SL mice and athymic nude mice inoculated with Ml leukemia 
cells. Mice treated with either calcitriol or la-hydroxyvitamin D3 
(la-OHDg) survived an average of 50% longer than did nontreated 
controls. These results indicate that calcitriol is effective in both 
inducing differentiation of Ml cells ^  vitro and in prolonging 
survival time of Ml cell-inoculated mice. 
Evidence strongly suggests that calcitriol induction of differen­
tiation in the transformed cell lines is receptor-mediated. Tanaka ejt 
al. (105) demonstrated that HL-60 cells express the calcitriol recep­
tor protein, and Olsson £t al. (99) reported that the U-937 cell line 
also expresses a similar high affinity receptor for calcitriol. 
Variant clones of HL-60, resistant to calcitriol-induced differentia­
tion, express lesser amounts of calcitriol receptor protein (106). 
Mangelsdorf £t al. (107) later reported that HL-60 cells responsive to 
calcitriol have approximately 4,000 high affinity calcitriol receptors 
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per cell (107), but a HL-60 variant line resistant to the growth and 
differentiation effects of calcitriol expressed less than 400 cal­
citriol receptor molecules per cell. These studies also demonstrated 
that the ability of several vitamin D metabolites to promote differen­
tiation correlates with their affinity for the calcitriol receptor, 
thus indicating that calcltrlol-induced differentiation of HL-60 to 
monocytes/macrophages is a receptor-mediated series of events. 
Effect of calcitriol on normal cells of the mononuclear phago­
cyte system The early studies in vitamin D-deficient animals that 
demonstrated a role for calcitriol in microbicidal host defense 
strongly suggested a direct effect of calcitriol on macrophage-assocl-
ated effector functions. This is the case, for calcitriol activates 
the cytotoxicity of alveolar macrophages (108) and enhances secretion 
of hydrogen peroxide by human monocytes and by U937 monoblast cells 
(109, 110). The secretion of oxygen reduction products, such as 
hydrogen peroxide (HgOg) and superoxide anion (0%) by mononuclear 
phagocytes, is increased during phagocytosis and is essential for 
tumoricldal and microbicidal activity (111). Rook £t £l. (112) showed 
that calcitriol induced an anti-tuberculosis activity in monocytes by 
controlling the proliferation of intracellular Mycobacterium 
tuberculosis. Calcitriol also induces fusion of alveolar macrophages 
(108, 113) and HL-60 promyelocytic cells (16), and also enhances 
secretion of interleukin-1 (IL-1) by monocytes (114). IL-1 is an 
established modulator of T and B lymphocyte proliferation and also 
induces collagenase and proteoglycanase activity in chondrocytes 
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(115) , which, in turn, may facilitate IL-1 stimulation of im vitro 
bone resorption (59). 
Other studies on the effects of calcitriol on monocytes have 
involved cellular adhesion and maintenance of adherence to substrate. 
Polla ejt al. (116) demonstrated that normal monocytes treated with 
calcitriol maintained adherence to tissue culture plastic as well as 
fibronectin-coated plastic. This study also reported calcitriol-
mediated protection of monocytes from thermal injury by increasing 
synthesis of heat shock proteins, protecting normal protein synthesis, 
and increasing recovery rate of normal protein synthesis after thermal 
stress (116). Franceschi et al. (117) later reported that calcitriol 
increases cell-associated fibronectin and concentrations of fibronec­
tin in growth media of MG-63 human osteosarcoma cells, TE-85 human 
osteosarcomas, SW-480 human colon carcinomas, and HL-60 myeloid 
leukemia cells. Accompanying the increased fibronectin synthesis by 
the MG-63 cells was an increase in cell adhesion (117). 
Fibronectin is a constituent surface glycoprotein of many normal 
cells that is present in lesser amounts or absent in malignantly 
transformed cells (118, 119). Accompanying the loss of FN in malig­
nant cells is lesser cell adhesion, rounded morphology, and loss of 
skeletal organization (120). The previous report with calcitriol-
treated HL-60 promyelocytic leukemia cells also showed increased 
adherence to plastic (16) accompanying the differentiation of cells 
along the monocyte-macrophage lineage. This report, coupled with 
evidence of calcitriol-stimulated fibronectin synthesis and increased 
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adherence demonstrated by Franceschl et al. (117), suggests that 
increased adherent capacity by cells also may be mediated by increased 
synthesis of fibronectin. Polla et al. (121) also demonstrated that 
calcitriol induces the binding of U937 cells to collagen, a component 
of the extracellular matrix, thus suggesting another mechanism for 
calcitriol-induced maintenance of adherence in cells of the mono­
nuclear phagocyte system. 
The calcitriol-induced differentiation of transformed cells along 
the monocyte/macrophage pathway also has been investigated for normal 
cells. In the presence of calcitriol, normal bone marrow cells 
demonstrated increased adherence and esterase activity and suppressed 
colony stimulating factor (CSF)-dependent formation of colony-forming 
units (15, 122). Clohisy et al. (123), however, reported that the 
inhibitory effect of calcitriol on colony formation was independent of 
CSF-1 and targeted through the adherent bone marrow-macrophage pre­
cursor. Accompanying differentiation was the up-regulation of the 
mannose receptor, a cell membrane receptor specifically associated 
with mononuclear phagocyte differentiation (124-126). Prowedini £t 
al. also reported that calcitriol-treated monocytes developed ^  vitro 
morphologic changes and increases in lysosomal enzyme activities that 
are characteristic of macrophage differentiation (127). In contrast 
to the studies reporting calcitriol-induced inhibition of myeloid 
leukemia cell growth and normal bone marrow-derived macrophage differ­
entiation, Munker et al. (102) reported that cells from the CSF-
dependent human myeloblast line (KG-1) and from normal human 
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granulocyte-monocyte stem cells (GM-CFC) were stimulated in their 
clonal proliferation by calcitriol in the presence of suboptimal CSF 
concentrations. 
The studies presented in this section demonstrate that calcitriol 
mediates profound effects on normal cells of the mononuclear phagocyte 
system which include inhibition of growth, differentiation, activation 
and production of H2O2, maintenance of adherence, and finally enhanced 
proliferation under certain suboptimal conditions. 
Parathyroid hormone metabolism and mechanisms of action 
Parathyroid hormone acts directly on bone and kidney and indi­
rectly on intestine through the stimulation of la-OHase and the 
resulting synthesis of calcitriol. A decrease in plasma calcium 
concentration below normal results in a rapid increase in PTH secre­
tion causing 1) an increase in calcium resorption from bone, 2) 
reduced renal excretion of calcium, 3) increased renal excretion of 
phosphate, and 4) enhanced efficiency of intestinal calcium absorption 
because of increased formation of calcitriol (128). 
Parathyroid hormone is a protein produced by the chief cells of 
the parathyroid gland. Biosynthesis and secretion of PTH involves an 
initially large precursor molecule, pre-pro-PTH (115 amino acids 
[a.a.]) (129-132), that undergoes proteolytic cleavages to yield first 
pro-PTH (90 a.a.) (133-134) and then the native hormone PTH (84 a.a.) 
(135-137). Pre-pro-PTH contains an additional 25 a.a. (-31 to -7) on 
the NHg terminus of pro-PTH molecule. This 25 a.a. sequence is 
believed to be the "signal-leader" sequence that permits binding to 
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the endoplasmic reticulum of polyribosomes synthesizing the secreted 
protein and directs and facilitates the transport of newly synthesized 
protein across the intracellular membrane. The "pre" segment is 
believed to be removed and degraded by proteolytic cleavage during 
this transit (138, 139). Pro-PTH (-6 to -1, 1-84 a.a.) then is 
transferred to the Golgi apparatus and converted to PTH (1-84 a.a.) 
(140). Parathyroid hormone subsequently is stored and secreted via 
secretory granules. Heterogeneity in the circulating forms, i.e., 
1-84, 1-34, 35-84, of PTH exists because of proteolysis that seems to 
occur at two physiological sites — within the parathyroid gland and 
in peripheral organs (128). Proteolysis in the peripheral organs 
occurs rapidly as shown by the rapid disappearance of intact PTH from 
the blood (t^yg ~ 1-10 min) coupled with simultaneous appearance of 
PTH fragments (141-143). Principal among the peripheral organs 
responsible for proteolysis is the liver, where Kupffer cells contain 
specific endopeptidases that generate both -NH2 and -COOH terminal 
fragments cleaved to form the NHg 1-34 a.a. PTH (144, 145). It is 
this 1-34 NH2 terminal fragment that is required for biological 
activity (146). The kidney seems responsible for removal of proteo-
lytically-formed carboxyl fragments (147, 148). Positions 1 and 2 of 
the 1-34 NH2 segment of PTH are essential for bioactivity (146), and 
the region 3 through 34 contains the structural determinants necessary 
for receptor binding (149-151). 
The mechanism of action of PTH involves interaction with a 
hormone-specific plasma membrane receptor. Hormone-receptor binding 
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Initiates a series of biochemical events that include: generation of 
cAMP via adenylate cyclase, intracellular entry of calcium, and 
phosphorylation of specific Intracellular proteins by PTH-activated 
kinases. This cascade of intracellular mechanisms ultimately leads to 
PTH-mediated biological activity in respective target cells. 
Effects of parathyroid hormone on mononuclear phagocytes, lympho­
cytes, and osteoblasts Parathyroid hormone Increases the metabolic 
activity and number of osteoclast in vivo (3,4). Parathyroid hormone 
also increases activity of osteoclasts in cultures of fetal rat bone, 
resulting in an increase in overall size of cells and an increase in 
area of the ruffled border and clear zone (152-155). Feldman et al. 
(156) reported that hormonally induced changes in osteoclast activity 
were correlated with PTH-induced fusion of pre-existing postmitotic 
mononuclear osteoclast precursors to form osteoclasts. The character­
istics and identity of the osteoclast precursor cells are unknown, 
although, as detailed earlier, evidence strongly suggests their origin 
is the less mature (monoblast, promonocyte) cells of the mononuclear 
phagocyte system. 
Monocytes and macrophages, more mature cells of mononuclear 
phagocyte system, have been Investigated for PTH-induced effects. The 
results of these studies are confusing and unclear. Yamamoto £t al. 
(157) demonstrated that circulating bovine lymphocytes, but not 
monocytes, contain the receptor for PTH. Adenylate cyclase activity 
was increased in PTH-treated lymphocyte cultures, but not in monocyte 
cultures treated with PTH. Perry et al. (158) also showed that 
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circulating human lymphocytes contain the PTH receptor and that cAMP 
accumulation increases threefold after a 5-min exposure of lymphocytes 
to PTH. PTH-induced changes in monocyte-macrophages, however, have 
been reported. Craig et al. (159) demonstrated increased lysosomal 
enzyme synthesis by culture monocytes treated with PTH, and Minkin e^ 
al. (160) reported increased cAMP accumulation in elicited mononuclear 
phagocytes in the presence of PTH. Stock et al. (161, 162), however, 
reported that PTH inhibits monocyte production of cAMP and also 
demonstrated that PTH decreased HgOg production and chemiluminescence 
in monocytes. 
The contradictory reports of a direct effect of PTH on monocytes, 
cells with no detectable PTH receptor expression, has led to the 
suggestion that cells, such as osteoblasts and/or lymphocytes that 
express the PTH receptor (157, 158, 163-165), serve a role in the 
PTH-induced effects on monocytes. A similar hypothesis for an inter­
mediate cell role, i.e., osteoblast, has been proposed for the osteo­
clast during the resorption process (166). Osteoclast expression of 
PTH receptors is controversial (167-170). Isolated osteoclasts do not 
resorb bone in vitro in the presence of PTH (171), but addition of 
osteoblasts in the presence of PTH (172) or conditioned medium from 
osteoblasts cultured with PTH or calcitriol does stimulate osteoclast 
bone resorption activity (173-175). These studies suggest that the 
osteoblast, as an intermediate cell, may mediate PTH-induced osteo­
clast bone resorption. Parathyroid hormone effects on monocytes and 
monocyte-mediated bone degradation may be mediated in a similar 
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fashion, although conditioned medium from osteoblast-like cells in the 
presence of PTH did not affect ^  vitro monocyte-mediated bone degra­
dation (175). 
Lymphocytes also may mediate a PTH-induced effect on monocytes. 
Whitfield et al. (176) first reported increased mitotic activity and 
increased cAMP accumulation in PTH-treated, thymic lymphocytes. 
Mitogen-stimulated lymphocytes elaborate a potent bone-resorbing 
factor(s) that has been termed osteoclast activating factor (OAF) 
(177). Products of activated lymphocytes also affect monocyte func­
tion. Nathan et al. (178) demonstrated an increase in adherence, 
phagocytosis, spreading, motility, and direct oxidation in macrophages 
treated with conditioned medium from antigen-sensitized lymphocyte 
cultures. Enhancement of adenylate cyclase activity in macrophages by 
activated lymphocytes also has been demonstrated by Remold-O'Donnell 
ejt al. (179). Additional evidence reported by Perry (180) that PTH 
stimulates lymphocyte production of factors that increase bone resorp­
tion suggests a possible physiological role for PTH-lymphocyte inter­
action in bone resorption. These studies by Nathan et al. (178) and 
Remold-O'Donnell et al. (179) suggest that PTH-activated lymphocytes 
also may influence monocyte-mediated bone degradation activity in a 
mechanism similar to that proposed for activation of osteoclast bone 
resorption. 
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Calcitriol Effects on Innnunoregulation 
Calcitriol receptors in cells of the immune system 
The initial unexpected findings that cells of hematolymphopoietic 
tissues express the calcitriol receptor suggested a role for cal­
citriol in the immune system. Reinhardt e^ al. (17) first discovered 
calcitriol receptors in calf thymus glands and lymph nodes. Further 
studies by Prowedini et al. (18) and Ravid e^ al. (19) demonstrated 
calcitriol receptor expression in the large, mature, mitotically 
active, medullary thymocytes, but not in the small, immature cortical 
thymocytes. Activated lymphocytes present in thymus and tonsils of 
normal children also contain a calcitriol receptor-like protein (182). 
Resting peripheral T and B lymphocytes, however, do not possess the 
calcitriol receptor, but ^  vitro activation of lymphocytes with 
Epstein Barr virus or mitogenic lectins, such as phytohemagglutinin 
(PHA) or concanavalin A (ConA), or by alloantigens in the mixed 
lymphocyte reaction results in expression of calcitriol receptor 
(20-22, 181, 182). Moreover, lymphocytes in patients with rheumatoid 
arthritis are activated and express the calcitriol receptor (183), and 
numerous T and B lymphocyte cell lines also express the calcitriol 
receptor (181). 
Prowedini et al. (21) and Bhalla et al. (20) demonstrated that, 
in contrast to resting T and B peripheral lymphocytes, monocytes 
constitutively express the calcitriol receptor. Myeloid leukemia cell 
lines and several monocytic precursor cell lines also express the 
calcitriol receptor. These cells in the presence of calcitriol 
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differentiate to a more mature monocyte-macrophage cell (13, 14, 98, 
101, 102, 105, 107). 
Effects of calcltrlol on thymocytes 
The studies demonstrating calcltrlol receptor expression in 
thymocytes suggested that the mature medullary thymocyte subpopula­
tions are targets for calcltrlol actions (18, 19). Prowedinl et al. 
showed that primary cultures of rat thymic lymphocytes in the presence 
of calcltrlol were protected against the spontaneous lytic involution 
evident in control culture in the absence of calcltrlol (184). Ravid 
et al. (19) and Koizumi a^. (25) also reported that murine medul­
lary thymocyte proliferative responses to PHA and IL-2, or IL-1 and 
IL-2 alone, was inhibited, but that calcltrlol had no effect on the 
cortical thymocyte subpopulations. The calcitriol-lnduced inhibitory 
effect could be abrogated by addition of high concentrations of IL-2, 
suggesting IL-2 suppression may be a factor responsible for cal-
citriol-medlated inhibition. These results suggested a possible role 
for calcltrlol in intrathymlc differentiation of T cells. 
Effects of calcltrlol on activated lymphocytes 
Stimulation of lymphocytes by mitogenic lectins leads to secre­
tion of lymphokines, lymphocyte proliferation and differentiation into 
effector cells. Mitogenic lectins or antigens in association with 
monocytes promote the lymphokine cascade that includes secretion of 
Interleukin 1 (IL-1) from activated monocytes, expression of the 
interleukin 2 receptor (IL-2Rec), and induction of IL-2 production by 
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activated T lymphocytes. The subsequent IL-2 binding to the IL-2Rec 
results In lymphocyte proliferation by an autocrine mechanism (185). 
The discovery that stimulated lymphocytes express the calcltrlol 
receptor Initiated a series of experiments to determine the effects of 
calcltrlol on lymphocyte proliferation, lymphoklne production, and 
differentiation. Tsoukas e^ al. (23) demonstrated that calcltrlol 
Inhibited the proliferation and the secretion of IL-2 of phytohemag-
glutlnln (PHA)-activated T lymphocytes. Other vitamin Dg metabolites 
were less effective than calcltrlol in suppressing IL-2. Their 
capacity to suppress IL-2 correlated with their affinity for the 
calcltrlol receptor, thus suggesting a receptor-mediated event for 
IL-2 suppression (23). Rlgby et al. (24) confirmed these findings and 
also reported that the calcltrlol-induced inhibition of lymphocyte 
proliferation could be attenuated but not abrogated by addition of 
exogenous IL-2. This attenuation Indicated that calcltrlol might be 
exerting its inhibitory effects at other points in lymphocyte mito-
genesls distinct from the inhibition of IL-2 secretion. Rigby et al. 
(186) later reported that calcltrlol also markedly inhibited produc­
tion of y-interferon (y-IFN) in PHA-induced T lymphocytes. Bhalla ^  
al. (187) discovered that calcltrlol inhibited the proliferative 
response of immune spleen and thymus cells to antigen but not to the 
lectin ConA. This report also demonstrated that calcltrlol inhibited 
IL-2 production of cloned la-restricted T cell hybridomas (calcltrlol 
receptor positive) activated with cloned la-bearing (calcltrlol 
receptor negative) stimulator cells. This study suggests that 
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calcitriol may be interfering with early events of antigen-induced T 
cell activation, possibly by Interfering with T cell recognition of 
relevant antigen on stimulator cell surfaces (187). Relevant to this 
hypothesis, Matsul et al. (188) examined the effect of calcitriol on 
several cell surface antigens on PHA-activated human PBM 1^ vitro. 
Expression of 0KT3* (peripheral T-cell), 0KT4* (helper/inducer T 
cell), and 0KT9* (transferrin receptor cell) markers were decreased 
significantly in the presence of calcitriol, but IL-2 receptor (Tac*) 
expression was unaffected by calcitriol. The Tg (0KT3*) molecule is 
present on all T lymphocytes and is believed to be Involved in the 
antigen-recognition process (189-191). Thus, these studies demon­
strating diminished expression of this molecule in the presence of 
calcitriol suggests that calcitriol-mediated inhibition of lymphocyte 
DNA synthesis may be the result to some extent of a direct effect on 
the T lymphocyte, specifically the antigen-recognition mechanism. 
Finally, as shown by Matsui al. (188), the evaluation of the 
effects of calcitriol on proliferation of mitogen-induced T lymphocyte 
subpopulations has demonstrated that both T helper/inducer and T 
suppressor cell populations are sensitive to the growth inhibitory 
effects of calcitriol (192, 193). 
Cell cycle analysis of calcitriol-induced inhibition of mltogen-
driven T lymphocyte proliferation has characterized more thoroughly 
this inhibitory effect. Rigby et al. (194) reported in flow cytometry 
studies of PHA-induced human PBM that calcitriol blocks transition 
from the early low RNA compartment, to late high RNA 
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compartment, and also demonstrated that calcltrlol does not affect 
IL-2 receptor expression. Additions of IL-2 or indomethacin, an 
inhibitor of prostaglandin production, attenuated the calcitriol-
induced suppression of DNA synthesis, but addition of IL-1 had no 
effect on reversal of calcitriol-induced inhibition. These findings 
suggested that, in addition to earlier reports of calcitriol-induced 
suppression of IL-2 production, calcitriol induces inhibition of 
proliferation via a prostaglandin-dependent component, possibly from 
enhancement of monocyte production of prostaglandin Eg in the presence 
of calcitriol (195). Manolagas et al. (196) also demonstrated that 
the antiproliferative effect of calcitriol on lymphocyte proliferation 
was not caused by interference with the calcium-dependent lymphocyte 
activation process nor by extracellular calcium, thus suggesting that 
alteration of calcium translocation flux across the cell membrane was 
not a factor in the inhibitory effects of the steroid hormone. 
Effects of calcitriol on B lymphocyte and cytotoxic lymphocytes 
also have been examined. Lemire et al. (197) demonstrated calcitriol-
induced suppression of PWM-induced proliferation and immunoglobulin 
production by human PBM. Iho et al. (198) also showed that activation 
of isolated human B lymphocyte cultures with either PWM or 
Staphylococcus aureus Cowan 1 in the presence of calcitriol resulted 
in suppression of proliferation and immunoglobulin production. 
Similar results showing calcitriol-induced inhibition of immunoglobu­
lin secretion have been reported for Epstein Barr virus-infected cells 
(199) and PWM-activated human PBM in serum-free culture conditions 
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(200). Komoriya et al. (201), by using a T cell-dependent antigen, 
sheep red blood cells (SRBC), and a T cell-independent antigen, 
trinitrophenyl-lipopolysaccharide, to stimulate immunoglobulin synthe­
sis in immune splenocytes, demonstrated that calcitriol-mediated 
inhibition of antibody production was evident only in the T cell-
dependent, antigen-driven system. These results suggest that inhibi­
tion of immunoglobulin synthesis by calcitriol may be mediated by the 
T lymphocyte and/or macrophage. Manolagas et al. (181), however, 
reported that Epstein-Barr virus-induced antibody production (T 
cell-independent response) was inhibited by calcitriol addition and 
that IL-2 additions did not reverse these inhibitory effects, thus 
suggesting once again that the effects of calcitriol on immune re­
sponse may be mediated through mechanisms other than suppression of 
IL-2 secretion. 
In contrast to the antiproliferative effects of calcitriol, Lacey 
et al. (26) reported calcitriol-induced stimulation of ConA-induced 
proliferation of a nontransformed T-helper cell line (D10.G4.1) in the 
absence of IL-1 or at low IL-1 concentrations. If, however, IL-1 
concentrations necessary for optimal response are employed, the 
calcitriol effect was inhibitory. My colleagues and I have demon­
strated in a previous study that calcitriol both inhibits and enhances 
ConA-induced DNA synthesis in normal bovine PBM (202). We reported 
that the contrasting effects of calcitriol on ConA-induced response 
were dependent on lymphocyte density, monocyte numbers, and basal 
rates of DNA synthesis. Calcitriol-mediated enhancement of ConA-
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Induced proliferation was evident typically when proliferation was 
suboptimal, whereas calcitriol-mediated inhibition was evident in 
cultures with high proliferation rates. A similar pattern of cal-
citriol-induced enhancement of cell growth has been shown in bone 
marrow cultures. Munker et £l. (102) demonstrated that normal human 
granulocyte-monocyte bone marrow stem cells were stimulated in their 
clonal proliferation by calcitriol in the presence of suboptimal 
concentrations of CSF. 
Effects of calcitriol on immune response-related monocyte functions 
Monocyte Class II MHC antigen expression and its role in antigen 
presentation (203, 204) and monocyte IL-1 production and its subse­
quent induction of IL-2 production (205, 206) and IL-2 receptor 
expression (207) are pivotal events in the early activation steps of 
lymphocyte proliferation. Evidence suggests that calcitriol increases 
both Class II MHC antigen expression and IL-1 production. Bar-Shavit 
et al. (16) reported increased expression of HLA-DR antigens (human 
Class II MHC) in HL-60 promyelocytic cells in the presence of calci­
triol, and Morel ^  £l. (208) demonstrated increased la antigen (mouse 
Class II MHC) expression in y^FN-induced myelomonocytic (monocyte 
tumor cell line) cell line WEHI-3. Enhanced expression of la mole­
cules by WEHI-3 lead to the increased capacity of these cells to 
stimulate antigen-specific, la-restricted T cell activation (208). 
The effect, however, of calcitriol on Class II MHC expression on 
normal monocytes is unknown. Calcitriol also may affect monocytes by 
increasing IL-1 production. Amento et al. (209) reported that IL-1 
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production by a lymphokine-induced immature monocytic cell line, U937, 
was augmented in the presence of calcitriol. Hodler e^ al. (210) also 
demonstrated that calcitriol increased IL-1 production by P388D cells, 
a murine macrophage cell line; Bhalla e£ al. (211) later showed that 
peripheral blood monocytes produced increased IL-1 following calcitriol 
treatment. 
Several recent discoveries also have suggested that calcitriol 
may act as an autocrine or paracrine factor in the microenvironment of 
immune responses. Extra-renal production of calcitriol initially was 
reported by Adams et al. (212, 213), who demonstrated ^  vitro produc­
tion of calcitriol from 25-OHD3 in primary cultures of alveolar 
macrophages from patients with sarcoidosis associated with hypercal­
cemia. Lymph node homogenates from a patient with sarcoidosis metabo­
lized 25-OHD3 to calcitriol, but lymph nodes from six normal persons 
failed to produce calcitriol (214). y-Interferon- or lipopolysac-
charide (LPS)-stimulated normal alveolar macrophages also convert 
25-0HD3 to calcitriol (215, 216), and Reichel et al. (217) also 
demonstrated that y-IFN-stimulated normal bone marrow macrophages 
synthesize calcitriol. These results suggest that calcitriol concen­
trations may be regulated in a paracrine fashion in the bone marrow 
and lungs via activated macrophage synthesis of calcitriol to 1) 
induce differentiation of cells of the mononuclear phagocyte system, 
2) enhance antigen processing via upregulation of Class II MHC antigen 
expression and IL-1 production by macrophages, and/or 3) induce 
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negative feedback loop on T lymphocyte proliferation by suppressing 
IL-2 production. 
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SECTION I. 
CALCITRIOL ENHANCEMENT OF CONCANAVALIN A-INDUCED 
BOVINE LYMPHOCYTE PROLIFERATION; REQUIREMENT 
OF MONOCYTES 
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INTRODUCTION 
1,25-Dihydroxyvltamin (calcitriol) regulates calcium homeo­
stasis and mediates its biological effects by interaction with a 
specific intracellular receptor (1). Recent studies have shown that 
calcitriol induces monocytic differentiation in murine and human 
myeloid leukemia cells (2-5) and that the thymus, monocytes, and 
activated T and B lymphocytes express the calcitriol receptor (6-9). 
Data from these studies suggested an immunoregulatory role for cal­
citriol. Calcitriol also inhibits proliferation of mitogen-stimulated 
peripheral blood mononuclear cells (PBM) (10, 11) and murine medullary 
thymocytes (12) and also suppresses interleukin-2 (IL-2) production 
(10, 11). In contrast to the well-documented antiproliferative 
effects of calcitriol, Lacey et. (13) reported that calcitriol 
stimulated proliferation of a nontransformed T-helper cell line in the 
absence of interleukin 1 (lL-1) or at low IL-1 concentrations while 
inhibiting proliferation at IL-1 concentrations necessary for optimal 
response. The present study demonstrates the effect of calcitriol on 
bovine lymphocyte mitogenesis and, more importantly, that calcitriol 
has both proliferative and antiproliferative activities in ConA-medi-
ated mitogenesis of nontransformed cells. 
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MATERIALS AND METHODS 
Cell Isolation and Enrichment 
Peripheral blood mononuclear cells (PBM), from 1- to 2-year-old 
Jersey heifers were isolated as previously described by using Percoll 
(Pharmacia, Piscataway, NJ) (14). PBM were recovered, washed twice in 
+ + + + 
Hank's balance salt solution (HBSS) without Ca and Mg , once in 
phosphate buffered saline (PBS), pH 7.2, and resuspended in RPMI 1640 
media containing 10 mM HEPES, pH 7.3 (Gibco, Grand Island, NJ), 
penicillin G (100 U/ml), and streptomycin (100 mg/ml). 
Nonadherent PBM were obtained by incubating PBM in RPMI 1640 with 
2 
10% heat inactivated fetal bovine serum (FBS) in 75 cm flasks (1.33 x 
10^ PBM/cm^) for 90 min at 39°C in 5% CO^ and 95% air. Nonadherent 
PBM were recovered by washing the flask twice with HBSS, centrifuging 
the pooled washes at 300 X g for 10 min, and resuspending in RPMI 
1640. These cells represented ~60% of PBM plated. 
Adherent PBM were prepared by plating 0.2 ml of increasing 
numbers of PBM (0.12, 0.25, 0.38, and 0.50 x 10^ cells/ml) into 
96-well, flat-bottomed microtiter plates and incubating for 90 min at 
39"C in an atmosphere of 5% CO^ in air. Nonadherent cells were 
removed by vigorous agitation of the plates and washing with HBSS. 
Nonadherent cells were reintroduced (0.25 and 0.5 x 10^ cells/ml) to 
evaluate mitogenesis with differing ratios of monocytes. Adherent 
cells prepared by this method represented an average of 18% of origi­
nal PBM plated and consisted of 84% monocytes as determined by alpha-
napthyl acetate esterase staining. Adherent cells (monocytes) prepared 
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3 by this procedure did not incorporate significant H-thymidine into 
DNA in response to ConA or calcitriol (data not shown). 
Culture and Proliferation Conditions 
Cells were cultured in 0.2 ml of RPMI 1640 with 6% heat-inacti­
vated FBS in 96-well plates. ConA, phytohemagglutinin (PHA), or 
pokeweed mitogen (PWM) (Sigma, St. Louis, MO) concentration, cell 
numbers, and relative percentages of monocytes (adherent) and nonad­
herent PBM varied as indicated in the figures. All culture conditions 
were examined in the presence or absence of l,25(0H)2Dg (obtained from 
Dr. M. Uskokovic, Hoffmann-La Roche, Inc., Nutley, NJ) added at the 
initiation of culture. Cells were cultured for 72 hr at 39"C in 5% 
CO^ and 95% air, pulsed 18 hr with 2 yCi of [methyl-^H]-thymidine 
(5.0 Ci/mmol, Amersham, Arlington Heights, IL), harvested onto glass 
fiber filters with a PHD cell harvester (Cambridge Technology, Inc., 
Cambridge, MA), and counted by liquid scintillation spectrophotometry. 
All assays were done in triplicate. Results were expressed as per-
3 
centage of [ H]-thymidine incorporation in cultures without calcitriol. 
Significant differences between treatment means were determined by 
least significant difference. 
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RESULTS 
Effect of Calcitriol on Bovine PBM Proliferation 
Bovine PBM mitogenic responses to PHA and PWM were inhibited by 
addition of 1-8 x 10 ^^M calcitriol (Fig. 1). The effect of cal­
citriol on ConA-mediated proliferation, however, was dependent on the 
magnitude of the proliferative response. Lymphocytes from cows with 
high inherent proliferative response (134,904 ± 15,488 cpm/well) were 
unaffected by calcitriol, whereas lymphocytes from cows with low 
initial proliferative response (46,317 ± 6,000 cpm/well) were signifi­
cantly stimulated by 2 to 8 x 10 ^^M calcitriol (Fig. 1). 
Effect of Adherent PBM (Monocyte) Addition on ConA-Induced 
Proliferation of Low- and High-Density Nonadherent PBM Cultures 
The data of Fig. 1 suggest that calcitriol-mediated enhancement 
of ConA-induced PBM mitogenesis is dependent on initial magnitude of 
the proliferative response. To establish vitro conditions in which 
the magnitude of ConA-induced mitogenesis is either low or high, low-
and high-density nonadherent PBM cultures supplemented with increasing 
numbers of monocytes (adherent cells) were examined for their prolif­
erative responses to ConA (Figs. 2a, b). High-density nonadherent PBM 
without monocyte supplementation were more responsive to ConA than 
were unsupplemented low-density nonadherent PBM cultures. Increasing 
monocyte numbers in both low- and high-density nonadherent PBM cul­
tures increased their proliferative response to ConA. 
43 
1 
8 
I 
5 
P<0.05 
P<O.OI 
0.2 
CALCITRIOL 
Figure 1. Effects of calcitriol on mitogenesis of bovine PBM. PBM 
(0.5 X 10 /ml) in 0.2 ml of medium were supplemented with 
either PHA (25 ug/ml, à), PWM (2.0 pg/ml, 0), or ConA 
(8.0 ug/ml, low-response cows, • , and high-response cows, 
•). Responses are expressed as percent (X ± SEM) of indi 
vidual controls in the absence of 1,25-(011)203. Mean ± SEM 
[^H]-thymidine incorporation (cpm) of PBM controls were; 
PHA (101,054 ± 18,867, n = 5), PWM (86,411 ± 18,648, n = 
4), ConA high response (134,904 ± 15,480, n = 4), and ConA 
low response (46,317 ± 6,000, n = 4). 
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Figure 2. ConA-induced mitogenesis of low-density (0.25 x 10 /ml). 
Fig. 2a) and high-density (0.5 x 10 /ml. Fig. 2b) non­
adherent PBM with increasing monocyte additions. Re­
sponses expressed as CPM (X ± SEM, n = 6). 
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Proliferation in cultures of low-density nonadherent PBM was more 
dependent on monocyte supplementation than were cultures of high-
density nonadherent PBM cultures. Proliferative responses of low-
density cultures were less than those of high-density cultures regard­
less of the number of monocytes added. 
Effect of Calcitriol on ConA-Induced Proliferation of Low- and 
High-Density Nonadherent PBM Cultures Supplemented with Monocytes 
The ConA-induced proliferative response in cultures of low-density 
nonadherent PBM was inhibited significantly, p < 0.05, by 0.48 to 0.96 
nM calcitriol. Monocyte additions to 7 and 13% of the total cells 
abrogated the inhibitory effects of calcitriol. Monocyte supplemen­
tation to 18 and 23% in the presence of calcitriol enhanced the 
proliferative responses by 80% (p < 0.01) as compared with responses 
of cultures without calcitriol (Fig. 3a). 
Proliferative responses of high-density PBM cultures to ConA were 
inhibited by calcitriol additions at all monocyte supplementation 
concentrations (Fig. 3b). The magnitude of inhibition by 0.48 and 
0.96 nM calcitriol, however, was attenuated significantly, p < 0.05, 
with increasing monocyte addition. Addition of calcitriol resulted in 
up to a 50% inhibition of the ConA-induced proliferation in cultures 
of high-density nonadherent PBM (without monocyte addition). Monocyte 
supplementation to 13% of total cells in high-density, nonadherent PBM 
cultures were, however, inhibited less than 15% with calcitriol 
addition (Fig. 3b). 
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Figure 3. Effect of calcitriol and monocytes on ConA-induced" 
lymphocyte proliferation. Responses are expressed as a 
percent of the mean [^H]-thymidine incorporation of con­
trols not treated with calcitriol (n = 6). (a) Low-
density nonadherent PBM supplemented with 0% (•), 7% 
(0), 13% (à), 18% (A), and 23% (•) monocytes (percent of 
total cells). ConA was present a 1 yg/ml. (b) High-
density nonadherent PBM cells supplemented with 0% (•), 
7% (0), 10% (A), and 13% (•) monocytes. ConA was 
present at 8 yg/ml. 
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DISCUSSION 
This study demonstrates that calcitriol inhibits PHA- and PWM-
stimulated bovine PBM proliferation as previously reported for human 
lymphocytes (10, 11). We have shown that lymphocytes from cows that 
had a high initial proliferative response to ConA were unaffected by 
calcitriol. We also have shown that lymphocytes from cows that had a 
low initial proliferative response to ConA had significantly greater 
proliferation rates in the presence of calcitriol. 
The role of initial proliferation rate on the calcitriol-induced 
effect was examined by supplemention of low- and high-density nonad­
herent PBM with different proportions of monocytes. The effect of 
calcitriol addition to low proliferation rate cultures (low cell 
density), in the absence of monocyte supplementation, was inhibition 
of proliferation. Monocyte supplementation to 18 and 23% of plated 
cells resulted in calcitriol-mediated enhancement of proliferation 
(Fig. 3a). The mechanism of calcitriol enhancement of ConA-induced 
proliferation is unknown. It may result from the ability of cal­
citriol to activate monocytes (15, 16) and Increase la expression 
(Class II MHC antigen) in immature monocytic cell lines (4, 17). 
Calcitriol also increases IL-1 secretion in a macrophage cell line 
(18) and augments IL-1 secretion in a monoblast cell line induced with 
conditioned medium from lectin-stimulated T lymphocyte cultures (19). 
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These effects of calcitrlol on monocytes may mediate the enhancement 
of suboptimal ConA-Induced responses. 
The addition of calcitrlol to high proliferation rate cultures 
(high cell density) also inhibited proliferation in the absence of 
monocytes. This Inhibition was attenuated by monocyte additions (Fig. 
3b). Previous work has shown that addition of exogenous IL-2 (11), 
but not IL-1, attenuates the inhibitory effects of calcitrlol (20) on 
proliferation. These data suggest that the monocyte-dependent attenu­
ation of the inhibitory effect by calcitrlol in high proliferation 
rate cultures, seen in our experiments, may involve reversal of 
calcltrlol-mediated IL-2 suppression. 
This study demonstrates that calcitrlol possesses both prolif­
erative and inhibitory effects on bovine ConA-induced proliferation, 
which are dependent on nonadherent PBM density, monocyte numbers, and 
basal rates of proliferation. These data suggest that monocytes 
mediate both calcltriol-lnduced enhancement of ConA-lnduced prolif­
eration in low-density cultures and attenuation of inhibition in 
high-density cultures. 
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SECTION II. 
PARATHYROID HORMONE ADMINISTRATION STIMULATES MONOCYTE-MEDlATED 
BONE DEGRADATION, AND CALCITRIOL ADMINISTRATION ENHANCES 
DNA SYNTHESIS IN CONCANAVALIN A-INDUCED BOVINE LYMPHOCYTES 
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INTRODUCTION 
Monocytes are located in regions of osteoclasts, which are the 
principal bone-resorbing cell of the body, and in regions of chronic 
inflammation, such as rheumatoid arthritis and periodontal disease 
(1-4). Recent evidence suggests a role for monocytes in the bone 
resorption process. Monocytes secrete products believed essential for 
bone resorption, such as lysosomal enzymes and collagenase (6), and 
monocytes degrade devitalized bone via a contact-mediated process (7, 
8). Additional studies suggest that monocytes may be recruited via 
chemotaxls to areas of resorbing bone (9, 10). Moreover, monocytes 
produce factors, such as interleukin 1 (IL-1) (11, 12), and certain 
prostaglandins (13) stimulate osteoclast bone resorption vitro. 
Monocytes also may serve an important role in the osteolytic process 
at sites of chronic inflammation. Inflammation-mediated osteopenia 
has been demonstrated in the rat (14). In addition, endotoxin treat­
ment of isolated monocytes has been shown to enhance vitro monocyte-
medlated bone degradation (15). These findings suggest that monocytes 
may play an Important role in the bone resorption process. 
The bone calcium mobilizing hormones, parathyroid hormone (PTH) 
and 1,25-dlhydroxyvitamln (calcitrlol), both mediate changes in 
monocyte function. Numerous studies have reported PTH-lnduced changes 
in monocyte functions. Craig £t al. (16) demonstrated Increased 
synthesis of lysosomal enzymes by cultured monocytes treated with PTH, 
and Mlnkin et al. (17) reported increased cAMP concentrations in 
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elicited mononuclear phagocytes treated with PTH. Stock e^ al., 
however, reported that PTH Inhibits production of cAMP and decreases 
HgOg production and chemllumlnescence In monocytes (18, 19). Despite 
these reports demonstrating effects of PTH on monocyte function, 
expression of PTH receptors on monocytes has not been demonstrated 
(20, 21). 
The effect of calcltrlol on monocyte characteristics and func­
tions are well established. Monocytes constitutlvely express the 
calcltrlol receptor, and calcltrlol has been shown to be a potent 
mediator of differentiation of mononuclear phagocytes. Calcltrlol 
Induces monocytic differentiation of myeloid leukemia cells (22, 23), 
normal bone marrow cells (24), and peripheral blood monocytes (25), 
Bar-Shavit ^  al. (26) also reported a direct dependency on calcltrlol 
for macrophage phagocytic function. This steroid hormone also acti­
vates alveolar macrophages (27) and stimulates enhanced oxidative 
metabolism in monocytes (28, 29). Finally, high-dose administration 
of calcltrlol to a patient with osteopetrosis, a disease characterized 
by osteoclast dysfunction, stimulated osteoclast bone resorption and 
increased vitro monocyte-medlated bone degradation (30). These 
reports suggest that PTH and calcltrlol affect functional characteris­
tics of monocytes and may also affect bone degradation activity. 
In addition to the roles of calcltrlol as a regulator of calcium 
homeostasis and as an Inducer of mononuclear phagocyte differentiation, 
recent studies have expanded the actions of calcltrlol to Include 
Immunoregulatlon. The discoveries of expression of calcltrlol 
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receptor in thymus, monocytes, and activated T and B lymphocytes 
(31-34) first suggested an iimnunoregulatory role. Further studies of 
immune response in lectin-induced peripheral blood mononuclear cells 
(PBM) demonstrated that calcitriol inhibited DNA synthesis and sup­
pressed interleukin-2 (IL-2) production (35-37). In contrast to these 
antiproliferative effects of calcitriol, Lacey et_ (38) reported 
calcitriol-induced stimulation of lectin-induced proliferation of 
nontransformed T-helper cell line (D10.G4.1) in the absence of, or at 
low interleukin-1 (IL-1) concentrations. However, calcitriol inhibited 
proliferative responses of DIO cells when IL-1 concentrations were 
optimal. We have demonstrated that calcitriol both inhibits and 
enhances concanavalin A (ConA)-induced DNA synthesis by normal bovine 
lymphocytes (39). These contrasting effects of calcitriol on ConA-
induced response were dependent on lymphocyte density, monocyte 
numbers, and basal rates of DNA synthesis. Calcitriol enhanced 
ConA-induced proliferation when conditions were suboptimal for prolif­
eration, whereas calcitriol inhibited proliferation when culture 
conditions were optimal (39). It is evident that calcitriol can exert 
both inhibitory and stimulatory effects on cells of the immune system, 
and that these effects are dependent on culture conditions. 
The studies cited in this report prompted the present investiga­
tion of the effect of vivo administration of PTH and calcitriol on 
in vitro bovine monocyte-mediated bone degradation, HgOg production by 
monocytes, and lectin-specific lymphocyte proliferation. Studies to 
date examining the immunoregulatory role of calcitriol and PTH have 
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concentrated on ^  vitro addition of these hormones. Thus, little is 
known of the effect of increased ^  vivo calcitriol or PTH concentra­
tions on subsequent in vitro responses of monocytes or lymphocytes. 
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MATERIALS AND METHODS 
Isolation of PBM 
Peripheral blood mononuclear cells from Jersey cattle were 
Isolated by gradient centrifugation by using 1.084 (g/ml) Percoll 
(Pharmacia, Piscataway, NJ) as previously described (40). PBMs were 
recovered, washed twice in Hank's balance salt solution (HBSS) without 
Ca and Mg , washed once in phosphate-buffered saline (PBS), and 
resuspended in 1.086 g/ml Percoll for further enrichment of monocytes 
with discontinuous gradient centrifugation. PBMs for lymphocyte 
proliferation studies were resuspended in RPMI 1640 containing 10 mM 
HEPES (Gibco, Grand Island, NJ), penicillin G (100 U/ml), and strepto­
mycin (100 yg/ml). 
Monocyte Isolation 
The two procedures employed for monocyte Isolation were: 1) 
adherence of PBMs to plastic and 2) Percoll discontinuous gradient 
separation of PBMs followed by adherence to plastic. Monocytes were 
Isolated by adherence to plastic by incubating PBM in RPMI 1640 with 
10% heat-inactivated fetal bovine serum (FBS) in 12-well (16 mm) 
plates (1.33 x 10^ PBMs/cm^) for 60 min at 39°C in 5% COg/SSB air. 
Nonadherent cells were removed by vigorous agitation of plates followed 
by washing Individual wells with HBSS. Adherent cells consisted of 
84% monocytes as determined by alpha-napthyl acetate esterase staining. 
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Total number of adherent cells was determined in a cell counter after 
removal of adherent cell population with trypsin. 
Monocytes also were isolated by Percoll discontinuous gradient 
centrifugation; A 3.75-ml layer of HBSS and 7.5-ml layers of 1.068, 
1.070, 1.072, 1.074, and 1.076 g/ml HBSS-diluted Percoll were under-
layered with 185 X 10^ PBM resuspended in 11.25 ml of 1.086 g/ml 
Percoll. The gradient was centrifuged at 320 X g for 30 min. Cells 
of the 1.068-1.070 g/ml interface band, which contained 60% nonspecific 
esterase-positive cells (monocytes), were harvested, washed twice in 
HBSS, resuspended at 2.5 x 10^ cells/ml in RPMI 1640 with 10% HBS, 
plated in 16-mm diameter wells at 1.0 ml/well, and incubated for 90 
min at 39°C in 5% air. Nonadherent cells were removed by 
vigorous agitation of the plate followed by washing individual wells 
with HBSS to remove remaining nonadherent cells. A volume of 0.9 ml 
of RPMI 1640 with 10% FBS was added to each well containing adherent 
cells. Adherent cells were 60% esterase-positive. 
Culture Conditions for Proliferation of 
Mitogen-Induced Lymphocytes 
PBM (0.5 X 10^/ml) were cultured in 0.2 ml of RPMI 1640 with 6% 
heat-inactivated FBS in 96-well plates. Concanavalin-A (ConA) (8.0 
yg/ml), phytohemagglutinin (PHA) (12.5 ug/ml), or pokeweed mitogen 
(PWM) (2.5 Mg/ml; Sigma, St. Louis, MO) was added to individual wells. 
Cells were cultured for 72 hr at 39°C in 5% C02/95% air, pulsed 18 hr 
with 2 yCi of [methyl-3H] thymidine (6.7 Ci/mmole, Amersham, Arlington 
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Heights, IL), harvested onto glass fiber filters with a cell harvester 
(Model PHD, Cambridge, MA), and counted by liquid scintillation 
spectrophotometry. All assays were done in triplicate. Results were 
3 
expressed as percentage of pretreatment [ H]-thymidine incorporation 
(cpm) for each animal. Relative changes in t^H]-thymidine incorpora­
tion of control animals in the calcitriol administration experiment 
were used to correct for assay fluctuations on a per day basis in the 
[3H]-thymidine incorporation of calcitriol-treated animals. 
Assay of Monocyte-Mediated Bone Degradation 
Monocyte-mediated bone degradation was based on a modification of 
the method of Teitelbaum e^ al. (41). ^^Ca-labeled bone was prepared 
45 in 100-g rats by seven subcutaneous injections of 150 pCi CaClg 
(DuPont, NEN Research Products) on alternate days for 14 days. Rats 
45 
were sacrificed five days after the last Ca injection. Long bones 
were removed, dissected free of periosteum, washed thoroughly in 0.9% 
NaCl, and air-dried for 7 days at 45°C. Fragments then were ground in 
a grinding mill (Brinkman/Retsch, Model ZM-1); the ground material was 
collected, dried in a desiccator for 3 days, and passed through a 
series of metal-sizing screens. Particles less than 38 wm in diameter 
were collected, sterilized by ultraviolet irradiation, resuspended in 
RPMI 1640 with 10% FBS at 4 mg/ml, and added in 0.1 ml volumes to 
individual monocyte culture at a final concentration of 400 ug bone 
fragments/well). Wells containing bone without monocytes served as 
controls. Wells containing monocytes without bone were used to 
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determine total monocytes per well. Monocytes were removed with 
trypsin following initial adherence and counted in a NOVA cell counter. 
Cultures were incubated at 39°C in 5% 002/95% air for 96 hr. Follow­
ing incubation period, upper half (0.5 ml) of each well was removed 
carefully, and ^^Ca content determined by liquid scintillation spectro­
photometry. Monocyte bone degradation activity was calculated by the 
following formula; 
45 
Ca in cultures with monocytes + bone particles 
-1 X 100 = Net % 
^^Ca in cultures with bone particles ^^Ca release/well 
per 2.0 X 10 
cells 
Monocyte numbers per well were not determined for PTH experiments and 
are reported as net % ^^Ca release/well. Triplicate wells of isolated 
monocytes from all animals were employed. 
Hydrogen Peroxide Production by Monocytes 
During PTH Injections 
Production of superoxide anion, O^, and resulting HgOg was 
determined fluorimetrically by using p-hydroxyphenylacetate (PHPA; 
Sigma, St. Louis, MO) described by Hyslop and Sklar (42). PHPA is 
oxidized to the stable fluorescent product 2,2'-dihydroxybiphenyl-
5,5'-diacetate (PHPA)2 by enzymatic reduction of H2O2 by horseradish 
peroxidase (Type VI, Sigma). Monocytes isolated by adherence and 
removed from plastic with trypsin (95% viable by Trypan blue exclusion) 
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were suspended in 0.15 M PBS, pH 7.2 at 25 x 10^ cells/ml. An assay 
mixture (7.5 yl) consisting of PHPA (10 mg/ml):horseradish peroxidase 
(8 mg/ml): superoxide dismutase (8 mg/ml) in a ratio of 25:10:10 was 
added to 2.5 ml Earle's balanced salt solution (BSS), pH 7.3, in 3-ml 
cuvettes. Monocytes (2.5 x 10^; 0.1 ml of stock cell solution) were 
added to each cuvette containing the assay mixture. Phorbol myristate 
acetate (PMA) then was added at a volume of 250 yl to cuvettes for a 
final PMA concentration of 1.0 yg/ml. Nonstimulated monocytes contain­
ing no PMA received 250 pi of PBS. Fluorescence was measured every 15 
min for total period of 30 min in a spectrofluorometer (Model SLM 
8000, SLM Instruments, Urbana, XL) with excitation and emission maxima 
of 323 and 400 nm, respectively. Net HgOg released was evaluated by 
subtracting non-PMA-stimulated fluorescence values from PMA-stimulated 
fluorescence values; 82^2 concentration was determined from standard 
curve. 
In vivo PTH Treatment of Jersey Calves 
Six Jersey bull calves 4 to 5 months of age (70-115 kg) received 
intramuscular injections (60 lU PTH/kg body weight) of crude synthetic 
N-terminal 1-34 fragment bovine PTH (767 lU/mg) (lot #009002, Pennisula 
Laboratories, Inc., San Carlos, CA) in .01 M acetic acid diluted in 
sterile 0.9% NaCl solution with 0.2% bovine serum albumin (BSA). 
Injections were given at 12-hr intervals for a total of nine injec­
tions in bone degradation studies to six injections in HgOg experi­
ment. Plasma and PBM samples for assays of bone degradation and DNA 
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synthesis (pre-treatment, treatment, and post-treatment) were obtained. 
All samples during treatment phase were taken immediately prior to 
injections. Monocytes for assays of bone degradation and PBM for 
assay of DNA synthesis in mitogen-induced lymphocytes were obtained 
prior to morning injection (a.m.) of PTH. Plasma samples were isolated 
by centrifugation and stored at -30°C for later evaluation. 
In vivo Calcitriol Treatment of Jersey Cows 
ALZET osmotic pumps, Model 2 ML Series (Alza Development Corp., 
Palo Alto, CA), were inserted in subcutaneous region of the paralumbar 
fossa under local anesthesia in six Jersey cows weighing between 350 
and 430 kg. Pumps contained 350 yg 1,25-(OH)20^ in 95% propylene 
glycol:5% ethanol. Pump rate was 11.5 ± 0.3 yl/hr. Sham surgery was 
performed on three Holstein steers used as controls. Plasma and PBM 
samples for assays of monocyte bone degradation and DNA synthesis in 
mitogen-induced lymphocytes (pre-treatment, treatment, and post-
treatment) were obtained. Plasma samples were isolated by centrifu­
gation and stored at -30°C for later evaluation. 
Plasma Assays 
Plasma Ca concentrations were determined by atomic absorption 
(Perkin Elmer 5000) (43), and plasma calcitriol concentration was 
determined by calf thymus receptor assay (44). 
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Statistical Analysis 
[®H]-Thymidine incorporation was expressed as a percentage of the 
mean pretreatment [®H]-thymidine incorporation (cpm) value for each 
animal; each animal served as its own control. 
Relative changes in [^Hj-thymidine incorporation of control 
animals in calcitriol administration experiment were used to correct 
for assay fluctuations on a per-day basis in calcitriol-treated 
animals. 
Significant differences of treatment means compared with pretreat­
ment mean in all experiments were determined by least significant 
difference. 
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RESULTS 
Plasma Calcitrlol and Calcium Concentrations of 
PTH- and Calcltriol-Treated Animals 
Calcitrlol and calcium concentrations in blood plasma from calves 
administered PTH and from cows implanted with osmotic pump containing 
calcitrlol are shown in Fig. 1 and 2. Injections of PTH caused a 
rapid, sustained hypercalcemia (day 1 to 5) (Fig. 2). Plasma cal­
citrlol Increased to 150 pg/ml after 24 hr of treatment. In response 
to hypercalcemia, calcitrlol concentrations returned to pretreatment 
concentrations 36 hr after initiation of PTH treatment and then 
declined below pretreatment concentrations for the duration of the 
treatment period in a manner previously described (45). 
Administration of calcitrlol via osmotic pumps resulted in a 
sustained Increase of plasma calcitrlol concentration to 100-170 pg/ml 
(Fig. 1). Plasma calcium concentrations increased and remained at 
11.5 to 12.5 mg/100 ml for days 2-8 (Fig. 2). 
Bone-Degrading Activity of Monocytes Isolated from PTH-
and Calcltriol-Treated Animals 
In vitro degradation of devitalized bone by monocytes was enhanced 
significantly by in vivo administration of PTH (Fig. 3). Bone degra­
dation activity increased significantly to 2.5X that of the pretreat­
ment value on day 3 of treatment. Monocyte bone degradation activity 
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PTH INJECTIONS I—1—1 
Pre I Pre 2 
Figure 1. Plasma calcitriol concentrations in bull calves during PTH 
injection experiment (#, n = 6), and in cows during osmotic 
pump delivery of calcitriol experiment (0, n = 6). Plasma 
calcitriol concentrations were determined by method of 
Reinhardt et al. (46). Time of treatment initiation is 
designated as day 0. PTH injection schedule and osmotic 
pump implant duration are indicated. Data are means + 
S.E.M. 
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Figure 2. Plasma calcium concentrations in bull calves during PTH 
injection experiment (#, n = 6), and in cows during 
osmotic pump delivery of calcitriol experiment (0, n = 6). 
Time of treatment initiation is designated as day 0. 
PTH injection schedule and osmotic pump implant duration 
are indicated. Plasma calcium concentrations were 
determined by atomic absorption. Data are mean + S.E.M. 
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Figure 3. Effects of PTH and calcitriol on bone-degrading activity 
of isolated bovine monocytes. Freshly prepared monocytes 
were isolated by Percoll discontinuous gradient centrifuga-
tion and adherence to plastic in PTH-treated animals 
(^» n = 6) and by only adherence to plastic in cal? 
citriol-treated animals ( , n = 6). Devitalized Ca-
labeled rat bone was added at initiation of culture (400 
Mg/well). Cultures were incubated for 4 days at 39°C in 
5% 003/95% air. Upon completion of culture, 0.5 ml of 
medium from each control and treated wells was removed and 
counted. Bone-degrading activity in PTH^experiment was 
expressed as net percentage increase in Ca release in 
wells containing monocytes and devitalized bone relative 
to wells containing devitalized bone alone. Bone-degrading 
activity in osmotic pump delivery^gf calcitriol experiment-
was calculated as net percentage Ca release per 2.0 x 10 
cells/well. Data are mean + S.E.M. Significance of 
difference from each pretreatment control culture 
designated as ** P < 0.10 and, **; P < 0.05. 
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returned to pretreatment levels during post-treatment period. This 
peak in bone degradation activity occurred when plasma calcitriol 
concentrations were significantly below pretreatment calcitriol 
concentrations (Fig. 2). This strongly suggested that PTH treatment 
and not calcitriol caused the stimulation of monocyte-mediated bone 
degradation. 
In vitro degradation of bone by monocytes was not affected by a 
sustained elevation of plasma calcitriol. Monocyte-mediated bone 
degradation activity also did not change in sham-operated controls 
(data not shown). These experiments strongly suggest that PTH is a 
potent mediator of monocyte-mediated bone degradation activity and 
that calcitriol, under the conditions examined, is without effect on 
subsequent vitro monocyte-mediated bone degradation. 
Phase Contrast Microscopy of Monocytes Isolated from 
PTH-Treated Calves During Bone Degradation Assay 
Because of the enhancement of bone degrading activity of isolated 
monocytes from PTH-treated animals, we sought to determine if any 
changes occurred in monocyte localization in bone degradation assay at 
the time of peak bone degradation activity. Figure 4 shows the 
monocytes isolated from a calf prior to the start of PTH treatment. 
Photographs of monocytes in culture with devitalized bone were taken 
at 24-hr intervals during a 72-hr incubation period. Initially, 
monocytes and bone particles are distributed uniformly (Fig. 4A). 
Small aggregates of bonr particles and cells were evident after 48 hr 
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Figure 4. Phase contrast microscopy of monocytes in bone degradation 
assay isolated from a bull calf before PTH administration 
(control cultures). Monocyte isolation and bone 
degradation assay were identical to that described in Fig. 
1. "b" represents bone particles; "ag", bone particle 
aggregates; "arrows", localization of monocytes. 
Photographs represent different incubation times for same 
isolated monocytes from calf prior to PTH treatment. 
Incubation times were: A. 0 hr (initiation of culture), 
B. 24 hr, C. 48 hr, and D. 72 hr. Magnification was 
200X. 
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in culture (Fig. 4C); monocytes are localized in areas of these bone 
aggregates after 72 hr in culture (Fig. 4D). 
Figure 5 shows the appearance of monocytes that were isolated 
from the same calf used to obtain the photographs in Fig. 4 after 6 
injections of PTH (day 3 of PTH treatment) in culture with devitalized 
bone. Monocytes and bone particles were distributed uniformly at 
initiation of culture (Fig. 5A) as shown for pre-PTH monocyte cultures 
(Fig. 4A). At 24 hr after initiation of culture, however, (Fig. 5B), 
large numbers of monocytes rapidly localized about bone aggregates and 
individual bone particles (Fig. 5B). Figure 5C shows the more rapid 
aggregation of bone particles associated with greater numbers of 
monocytes. Methylene blue staining of monocytes showed monocytes 
localized on top of bone particles (photographs not shown). Monocyte 
localization increased with increasing time of incubation as shown in 
72-hr culture photograph (Fig. 5D). Monocytes surrounding these 
monocyte-bone aggregate islands appear larger and more elongated 
compared with pre-treatment cultures. 
Hydrogen Peroxide Production by Monocytes Isolated 
from PTH-Treated Calves 
To delineate further a possible mechanism for the PTH-induced 
increase in monocyte-mediated bone degradation, HgOg production by 
monocytes from PTH-treated calves was measured (Fig. 6). As stated in 
the legend, HgOg production of pretreatment samples from control and 
PTH-treated differed prior to treatment. Therefore, HgOg production 
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Figure 5. Phase contrast microscopy of monocytes in bone degradation 
assay isolated from bull calf after 3 days of PTH treatment 
(6 injections). Monocyte isolation and Ijone degradation 
assay were identical to that described in Fig. 1. "b" 
represents bone particles; "ag", bone particle aggregation; 
"arrows" indicate localization of monocytes. Photographs 
represent different incubation times for isolated monocyte 
cultures from PTH-treated calf of Fig. 4. Incubation times 
were; A. 0 hr (initiation of culture), B. 24 hr, 
C. 48 hr, and D. 72 hr. Magnification was 200X. 
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Figure 6. Effect of PTH (6 injections) administration to bull calves 
on monocyte production of hydrogen peroxide. Monocytes 
from 6 PTH-treated calves and 4 carrier-treated calves were 
isolated by adherence as described in Methods section and 
were evaluated fluorimetrically for superoxide anion 
production by the method of Hyslop and Sklar (42). Phorbol 
myristate acetate (PMA)-stimulated 0% production by 
monocytes was determined after subtraction of Og resting 
(non-PMA) monocytes. Results were reported as net % HgOg 
released/30 min x 2.5 x 10 cells relative to pre-treatment 
values. Pre-treatment H2O2 concentration values were: 
PTH-treated animals (0) = 58 ± 10 pmol H2O2/3O min x 2.5 x 
10 cells, n = 6; control animals (•) = 100 ± 21 pmol 
H2O2/3O min X 2.5 x 10 cells, n = 4. 
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by monocytes relative to pretreatment values for each calf are pre­
sented. As shown in Fig. 6, PTH treatment resulted in enhanced HgOg 
production by day 3 of treatment to 4.5 X the pre-treatment values. 
Injection of carrier alone to control calves was without significant 
effect. These data suggest that PTH treatment enhances produc­
tion on the same day of peak monocyte-mediated bone degradation 
activity (Fig. 3). This enhancement suggests that PTH may be stimu­
lating an inflammatory-type mechanism that mediates the enhanced bone 
degradation activity by isolated monocytes. 
Mitogen-Induced DNA Synthesis in PBM Isolated from 
PTH- and Calcitriol-Treated Cattle 
To determine the effect of plasma calcitriol on ^  vitro DNA 
synthesis in mitogen-induced PBM, plasma calcitriol concentrations 
were increased for 5 to 6 days by osmotic pump administration of 
calcitriol and for 1 to 2 days by PTH injections. 
Parathyroid hormone administration resulted in a significant 
inhibition of (P < 0.05) vitro DNA synthesis of PWM-stimulated 
lymphocytes (Fig. 7C). On day 1 of PTH treatment, DNA synthesis was 
55% of pre-injection values (Fig. 7C). Inhibition occurred on the day 
of peak calcitriol concentrations (see Fig. 1). Lymphocyte prolifera­
tive response to PWM returned to pretreatment values on days 3, 4, and 
5 of treatment, which is when plasma calcitriol concentrations were 
markedly lower (Fig. 1). PTH injections and subsequent increase in 
73 
A PTH INJECTIONS 
"I I—I 1 1 1 1 1—I 1 
80-
— 70-
S 60 -
P<0.05 
DAYS 
Figure 7. Effect of PTH administration to bull calves on in vitro 
DNA synthesis in mitogen-induced PBM. PBM (0.5 x 10 /ml) 
that were isolated by Percoll density centrifugation from 
PTH-treated bull calves were stimulated with PHA (12.5 
yg/ml), (0, n = 5), ConA (7.8 Mg/ml) (A, n = 5), or PWM 
(2.5 ug/ml) (#, n = 4), added at initiation of culture. 
PBM were incubated for 72 hr at 39°C in 5% €02/95% air, 
pulsed for 18 hr with 2 yCi [methyl-^Hj-thymidine, 
harvested onto glass fiber filters, and assessed for DNA 
synthesis by liquid scintillation spectrophotometry. 
Results are expressed as percentage of pretreatment 
[^H]-thymidine incorporation, allowing each calf to act as 
its own control. Mean ± S.E.M. of [^Hj-thymidine 
incorporation (CPM) of pretreatment controls were: ConA 
(453,193 ± 45,456), PHA (436,037 ± 57,031), and PWM 
(269,633 ± 19,013). 
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plasma calcitriol had no effect on DNA synthesis in ConA- or PHA-
stimulated lymphocytes (Fig. 7A and 7B). 
Treatment of cows with calcitriol also caused a significant 
inhibition (P < 0.05) of DNA synthesis in PWM-stimulated lymphocytes 
(Fig. 8C). Inhibition of proliferative response to 60% of that for 
pretreatment value was evident on day 3 (Fig. 8C). This inhibition 
coincided with an increase in plasma calcitriol concentrations to 160 
pg/ml (Fig. 1). ConA- and PHA-induced PBM mitogenic responses, 
however, were enhanced greater than 70% of pretreatment by day 2 of 
calcitriol treatment (Figs. 8A and 8B). Mitogenic response to PHA was 
unaffected by sustained plasma calcitriol increase on treatment days 
2-3 but increased to values twice that of pretreatment values during 
post-treatment interval (Fig. 8B). ConA-induced proliferative re­
sponse, however, remained markedly enhanced throughout the treatment 
period and coincided with increases in plasma calcitriol (Fig. 1 and 
Fig. 8A). ConA-induced proliferative response returned to pretreatment 
values within 3 days after pump removal (Fig. 8A) and was associated 
with a return of plasma calcitriol concentrations to pretreatment 
levels (Fig. 1). 
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Figure 8. Effect of calcitriol administration to cows on Iji vitro 
DNA synthesis in mitogen-induced PBM, Osmotic pumps 
calcitriol were implanted surgically in the subcutaneous 
region of paralumbar fossa in 6 Jersey cows. PBM were 
isolated and cultured as described in Methods section and 
legend of Fig, 4. Results are expressed as percentage of 
pretreatment [®H]-thymidine incorporation relative to 
control (non-implant) cows. Mean ± S.E.M. of [^H]-
thymidine incorporation (CPM) of pretreatment controls 
were: ConA (246,531 ± 32,274), PHA (223,428 ± 30,467), and 
PWM (40,797 ± 6,804). 
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DISCUSSION 
The study of monocyte function in this report demonstrates that 
PTH administration ^  vivo stimulates both ^  vitro monocyte-medlated 
bone degradation and HgOg production. These results suggest a possi­
ble inflammatory-type mechanism for the PTH-induced increase in bone 
degradation activity of monocytes. 
The cellular events directing the PTH-induced enhancement of 
monocyte-mediated bone degradation is unknown. Previous studies have 
demonstrated that ^  vitro PTH treatment increases cAMP production in 
mononuclear phagocytes and decreases chemiluminescence and cAMP 
production while increasing lysosomal enzyme production in monocytes 
(16-19). These studies suggested that PTH treatment can mediate a 
direct effect on cells of monocyte-macrophage lineage. These studies 
would suggest that PTH administration directly stimulates monocyte-
mediated bone degradation via a cAMP-mediated process or by an in­
crease in lysosomal enzymes, or collagenase. This proposal seems 
unlikely because previous studies have been unable to demonstrate PTH 
receptor expression in the monocyte (20, 21). A more plausible 
explanation for our results is that a PTH responsive accessory cell 
mediated the observed PTH effect. 
An intermediate role for the osteoblast in stimulating osteoclast 
bone resorption has been proposed by Rodan et al. (46). This hypothe­
sis was formulated because of the inability to demonstrate PTH recep­
tor on osteoclasts (47, 48) and the lack of evidence for any direct 
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effect of PTH on Isolated osteoclasts (49, 50). These data and data 
demonstrating that PTH stimulates osteoblasts to release factors that 
Increase osteoclast bone resorption (51) points to the osteoblast as a 
mediator of PTH effects on osteoblasts. Therefore, a PTH responsive 
cell such as the lymphocyte (20, 21) may play an intermediate role in 
stimulation of monocyte-mediated bone degradation we observed. 
Studies have suggested a role for the thymus gland and lymphoid 
cells in the bone resorption mechanism. Milhaud e£ al. (52) reported 
that thymus atrophy and associated bone resorption dysfunction in the 
op/op (osteopetrotic) rat could be cured by transplantation of normal 
thymus gland into affected animals. Marks elt al. (53) also demon­
strated that bone resorption was restored in ia/ia (inciser absent-
osteopetrotic) rats by infusion of mononuclear cell isolates from 
thymus (99% lymphocytes, 1% monocytes) of normal littermates. Fur­
thermore, bovine and human lymphocytes express the PTH receptor and 
demonstrate increased cAMP accumulation after PTH treatment (20, 21). 
PTH stimulation of lymphocyte synthesis of factors that increase bone 
resorption (54) are further evidence that a physiological role for 
PTH-lymphocyte interaction in bone resorption may exist. Although 
these reports suggest a role of lymphocytes in osteoclast bone resorp­
tion, the role of lymphocytes in monocyte-mediated bone degradation 
has yet to be examined. 
The increase in HgOg production by isolated monocytes from PTH-
treated animals suggests that PTH activates circulating monocytes in a 
manner similar to that evident in an inflammatory response. Monocytes 
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are found in regions of chronic Inflammation and associated osteolysis 
evident In rheumatoid arthritis and periodontitis (1-5) and HgOg is 
formed and released during the respiratory burst of phagocytes during 
the inflammatory response. Inflammation-associated secretory products 
of macrophages Include lysozyme and collagenase (55), and macrophages 
activated with endotoxin, a modulator of Inflammatory response, 
secrete increased amounts of collagenase (56, 57). Endotoxin also 
increases vitro chicken monocyte- and murine macrophage-medlated 
bone degradation (15), but another study reported inhibition of bone 
degradation activity in endotoxln-activated murine macrophages (58). 
Associated with PTH activation of monocyte inflammatory functions in 
this study, i.e., HgOg production, may be an Increase in collagenase 
production by monocytes thus possibly increasing the bone-degrading 
activity of Isolated monocytes from PTH-treated calves. 
Heersche (59) and Mundy (60) have proposed an accessory-"helper-
scanvenger" role for monocytes in the removal of debris from areas of 
osteoclast bone resorption. Baron £t al. (61) also demonstrated that 
initiation of bone remodeling, as studied in tooth egression in the 
rat, occurs during the activation phase of bone remodeling and Involves 
the recruitment of cells with mononuclear phagocyte characteristics to 
areas of bone. Additionally, Chambers and Fuller (62) demonstrated 
that digestion of unmlneralized organic material by osteoblasts 
exposes bone mineral surfaces to osteoclasts. Monocytes, recruited to 
areas of bone resorption during the recruitment/activation phase of 
bone remodeling, also may remove osteoid matrix by secretion of 
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collagenase and thus facilitate osteoclast contact and resorption of 
mineral surfaces. Our data suggest that the circulating monocyte is 
responsive to PTH, either directly or indirectly via an intermediate 
cell such as the lymphocyte. PTH-activated monocytes may be recruited 
to areas of bone resorption as shown in our vitro model, indicating 
that isolated monocytes from PTH-treated animals rapidly accumulated 
around bone aggregates. Once recruited, monocytes may aid osteoclast 
bone resorption by removal of the osteoid matrix and/or removal of 
bone debris resulting from osteoclast activity. 
In addition to the investigation of monocyte-mediated bone 
degradation, I examined the iji vitro proliferative response of lympho­
cytes to mitogens following calcitriol administration. Periods of 
increased plasma calcitriol were of 1- to 2-day duration in the PTH 
experiment and of 7-day duration when osmotic pumps continuously 
infused calcitriol. The present study suggests that, as shown in 
previous in vitro studies in humans and cattle (37, 39), that cal­
citriol inhibits the PWM-stimulated bovine lymphocyte proliferative 
response of bovine lymphocytes during the period of increased plasma 
calcitriol concentration. Our results demonstrating enhanced PHA- and 
ConA-induced responses of isolated lymphocytes during calcitriol 
treatment contrast with studies reporting ^  vitro inhibition of PHA-
and ConA-stimulated lymphocyte proliferation in the presence of 
calcitriol (35, 36, 39). Rigby et al. (36), however, reported that 
calcitriol must be present during the first 12-18 hr of PHA-induced 
mitogenesis; otherwise, a significant loss in the inhibitory effect of 
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calcitriol occurs. Calcitriol is not present during mitogenesis in 
the present study, and the findings demonstrate that calcitriol 
administration to cattle prior to lymphocyte isolation results in the 
enhancement of DNA synthesis in PHA- and ConA-induced lymphocyte. 
The mechanism of enhanced ConA- and PHA-induced proliferation 
resulting from calcitriol treatment is unclear. Earlier studies have 
shown calcitriol-induced enhancement of lymphocyte proliferation. 
Tsoukas ^  al. (35) reported a significant increase in PHA-induced PBM 
-12 
proliferative response at 1 x 10 M calcitriol. This observation 
was evident in a 2-day incubation study at low proliferation rates, 
but the authors were unable to reproduce this phenomenon. Lacey et 
al. (38) also have demonstrated calcitriol-induced augmentation of 
proliferation of ConA-induced nontransformed T helper cells. Studies 
conducted in our laboratory demonstrated that low proliferation rate 
cultures of ConA-stimulated bovine lymphocytes supplemented with 
increasing monocyte additions showed enhanced proliferative response 
in the presence of calcitriol (39). We suggested that the monocyte 
may be the mediator of the calcitriol-induced enhancement either by 
increasing la expression and/or increasing IL-1 synthesis, which are 
two pivotal events in the early activation steps of lymphocyte prolif­
eration. Monocytes constitutively express the calcitriol receptor, 
whereas T and B lymphocytes do not (32, 33). This differential 
expression suggests that the monocyte and not T and B lymphocytes is 
responsive to calcitriol in this study, and thus the monocyte is the 
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likely mediator of the calcitriol-induced enhancement of proliferation 
in the present study. 
The manner by which the monocyte may mediate calcitriol-induced 
enhancement of ConÂ-stimulated proliferative response, as stated 
earlier, is unclear. Several studies have shown that ConA-stimulated 
lymphocyte proliferation requires an la-bearing accessory cell (63-65), 
and this requirement may be a mechanism of the enhancement of ConA-
stimulated proliferative response in the present study. Calcitriol 
increases expression of HLA-DR (human Class II) antigens in HL-60 
leukemia cells (23), and also increases la antigen expression in 
IFN-a-induced monocyte tumor cell line WEHI-3 (66). Circulating 
monocytes, which all express Class II antigen to varying degrees, may 
possess higher Class II expression on a per-cell basis as a result of 
in vivo calcitriol treatment. This isolated monocyte population then 
would be more effective at antigen presentation than isolated pre-
treatment monocytes in ConA-stimulated PBM culture conditions result­
ing in augmentation of proliferation. Additionally, calcitriol 
treatment may cause an increase in IL-1 synthesis by monocytes. 
Calcitriol-treated monocytes, a macrophage cell line, and lymphokine-
induced U937 cells (immature monocyte cell line) demonstrate increased 
production of IL-1 (67-69). Lacey ^  £l. (70) also reported that a 
normal nontransformed IL-1 dependent T helper cell line (variant of 
DIO G4.1), when exposed to IL-1 and IL-2, showed a marked synergistic 
effect on growth promotion. In the present study, if monocytes 
isolated from calcitriol-treated animals do indeed have enhanced IL-1 
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production capacity, then the increased IL-1 production may act with 
IL-2 that is produced by T cells during Iji vitro ConA-induced response 
to cause a synergistic enhancement of lymphocyte proliferation. 
The calcitriol-induced enhancement of ConA-induced lymphocyte 
proliferation also may result from the induction of growth factor 
receptors. Lacey e£ al. (38) reported that calcitriol increased IL-2 
receptor expression in DIO G4.1-T helper cells. Recently, a study by 
Lichtman et al. (71) demonstrated that the DIO G4.1 cell line, classi­
fied as a type 2 helper (TH^) cell (72), responds in an autocrine 
growth-type mechanism by secreting B-cell stimulatory factor 1 (BSF-1, 
IL-4) and also proliferating in resonse to BSF-1. Lichtman e£ al. 
(71) also observed that DIO cells respond to IL-1 and BSF-1 together 
but not to BSF-1 alone and that DIO cells also respond to IL-2 alone. 
In the present study, calcitriol administration may increase IL-1 
secretion in circulating monocytes as suggested earlier, and this 
increase in IL-1 secretion then may potentiate the responsiveness of 
THg subpopulations to BSF-1 or IL-2 by upregulating the BSF-1 or IL-2 
receptor, thus resulting in augmentation of ConA-induced prolifera­
tion. 
Furthermore, the enhanced ConA-induced lymphocyte proliferative 
response may result from shifts in circulating T lymphocyte subpopula­
tions during calcitriol administration. The OKT4/OKT8 (T„-helper-
inducer/Tg-suppressor T cell) ratio is reported to be significantly 
greater in osteopetrotic patients compared with that of nonosteo-
petrotic patients (73). Administration of la-hydroxyvitamin D^, 
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however, resulted in a significant decrease in the T^/Tg ratio sug­
gesting either a decrease in cells or an increase in Tg cells (73). 
Hersey et al. (74) also reported that solarium exposure to normal 
volunteers increased in Tg suppressor/cytotoxic T cells and a signifi­
cant decreased T^/Tg ratio. Exposure to sunlight increased vitamin D 
synthesis in the skin, but unfortunately Hersey ^  al. (74) did not 
evaluate calcitriol plasma concentrations in these volunteers. In our 
present experiment, calcitriol administration may cause a shift in the 
Tjj/Tg ratio and thus alter the ConA-stimulated DNA synthesis of 
lymphocytes isolated from calcitriol-treated animals relative to 
pre-calcitriol-treated lymphocyte response. 
The inhibition of ^  vitro PWM-induced lymphocyte proliferation 
during calcitriol treatment and during PTH-stimulated increases in 
plasma calcitriol also suggests an Inhibitory role of calcitriol. 
These results correspond to ^  vitro studies of calcitriol-induced 
inhibition of PWM-stimulated human and bovine lymphocytes (37, 39). 
This inhibition of PWM-induced proliferation suggests, as proposed 
earlier for calcitriol-induced enhancement of ConA-stimulated lympho­
cytes, that the monocyte, which expresses the calcitriol receptor 
during calcitriol administration, may mediate the apparent calcitriol-
induced inhibition of lymphocyte proliferation. The lack of sustained 
inhibition of PWM-induced lymphocyte proliferation during the 6-day 
period of elevated plasma calcitriol is, however, puzzling and warrants 
caution in attributing any inhibitory role for calcitriol in 
84 
experiments of ^  vivo calcitriol administration and the subsequent 
PWM-Induced lymphocyte proliferation. 
This study Investigated the effect of PTH and calcitriol adminis­
tration in the bovine on the subsequent vitro DNA synthesis in 
mitogen-induced lymphocyte. PTH administration did not change either 
the ConA- or PHA-induced lymphocyte proliferation but did inhibit 
PWM-induced proliferative response on the day of peak plasma cal­
citriol concentration. Calcitriol administration, however, either did 
not affect or enhanced the PHA-induced proliferative response. ConA-
induced proliferative response was enhanced markedly throughout 
calcitriol administration. The lymphocyte proliferative response to 
PWM also was unaffected by calcitriol administration, except for a 
one-day period of inhibition. The principal finding of this study 
suggest that calcitriol administration to animals does not inhibit the 
subsequent in vitro DNA synthesis by lymphocyte. On the contrary, DNA 
synthesis in ConA-induced lymphocyte is augmented significantly 
following calcitriol administration. I propose as for my earlier 
finding of vitro calcitriol-induced enhancement of ConA-induced 
proliferative response under low proliferative rate cultures condi­
tions (39) that the monocyte is the mediator of the enhanced prolifer­
ation. Calcitriol may act to increase monocyte la expression and/or 
IL-1 synthesis, which are two pivotal events in the early activation 
steps of lymphocyte DNA synthesis. This potentiation of the early 
activation steps may result in the enhancement of stimulation of 
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subset populations of T cells. I.e., Type 2 helper cells, possibly by 
upregulation of IL-2 and/or BSF-1 receptor expression. 
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SECTION III. 
MILK FEVER 
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INTRODUCTION 
My discovery that PTH administration to bull calves resulted in 
an increase in monocyte-mediated bone degradation prompted me to 
evaluate the bone degradation activity of monocytes isolated from cows 
with parturient paresis (milk fever). Milk fever is a disease 
characterized by end-organ resistance to the calcium mobilizing 
hormones, PTH and calcitriol, seen at the onset of lactation (1). 
Preventative measures include a prepartal low-calcium diet (2) and 
prepartal exogenous PTH administration (3). Both of these strategies 
are designed to prime bone calcium mobilization for calcium demand at 
lactation. The basis for evaluating monocyte-mediated bone degrada­
tion is a study by Key £l. (4) in an osteopetrotic child. Osteo­
petrosis is also an end-organ-resistant disorder characterized by 
dysfunction of bone resorption mechanism. Key ^  £l. (4) administered 
high-dose calcitriol to this osteopetrotic child and found that both 
osteoclast bone resorption and monocyte-mediated bone degradation were 
increased significantly as a result of calcitriol treatment. We, 
therefore, sought to determine if monocyte-mediated bone degradation 
was affected during clinical milk fever relative to pre- and post-milk 
fever bone degradation activity. 
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MATERIALS AND METHODS 
Parturient Paresis (Milk Fever) Experiment 
Periparturlent Jersey cows with histories of parturient paresis 
were fed a high calcium diet that predisposes the cow to milk fever 
beginning at 6 weeks prepartum. The diet for the first 4 weeks of the 
6-week prepartal period supplied approximately 110 g Ca and 33 g P 
dally. At approximately 2 weeks prepartum and for the first 2 weeks 
of lactation, cows were fed a diet that supplied approximately 150 g 
Ca and 78 g P dally. Plasma and PBM samples for monocyte isolation 
and bone degradation assay were taken at regular intervals, but more 
frequently at days around parturition. At onset of clinical signs of 
milk fever, calcium borogluconate was administered immediately after 
plasma and PBM samples were taken. The prepartal and postpartal 
periods were divided into different day intervals as indicated in the 
figures. 
Monocyte Bone Degradation Assay 
Monocytes were isolated and evaluated for bone degradation 
activity as detailed in the Materials and Methods of Section II. 
Plasma Evaluation During Periparturlent Period 
Calcium, PTH, and calcltriol concentrations in plasma were 
determined by methods detailed in the Materials and Methods of Section 
II. 
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RESULTS 
Monocyte-Medlated Bone-Degrading Activity and Calcitriol, 
PTH, and Calcium Concentrations in Plasma of Parturient 
Paretic (Milk Fever) Cows 
Plasma calcium and calcitriol concentrations (Fig. IB) and plasma 
PTH concentrations (Fig. lA) from three paretic cows are shown in Fig. 
1. Plasma calcium concentrations begin declining on days -2 to -1 and 
are decreased significantly (P < 0.01) at onset of milk fever and on 
days 1 and 2 post-milk fever (P < 0.01) (Fig. lA). PTH stimulation of 
renal la-(OH)ase activity and low plasma calcium concentrations (5) 
result in an increase in plasma calcitriol concentrations at onset of 
milk fever and on days 1 to 2 and 3 to 4 (P < 0.01) post-milk fever. 
Horst e^ £l. (6) previously have shown that PTH and calcitriol concen­
trations are not different in paretic and nonparetic cows and 
suggested that a primary hormone resistance to these calcitropic 
hormones may be a cause for onset of milk fever. We have measured the 
bone-degrading activity of monocytes from milk fever cows at the onset 
of milk fever and compared this activity to bone degradation activity 
of pre- and postparetic cows. As shown in Fig. lA, monocyte bone 
degradation activity decreased on days -4 to -3 relative to days -9 to 
-5 degradation activity, and then increased significantly on days -2 
to -1 to 2.5 X the activity.of days -4 to -3. This increase in bone 
degradation activity of monocytes was coincident with an increase in 
plasma PTH concentration (Fig. lA). At the onset of milk 
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Figure 1. Plasma calcium, calcitriol, and PTH concentrations and 
the bone-degrading activity of monocytes from Jersey cows 
before, during, and after onset of milk fever. Determina­
tion of PTH, calcitriol, and calcium concentrations in 
plasma are described in Materials and Methods of Section 
II. Experimental protocol for monocyte isolation and bone 
degradation assay is the same as for PTH administered to 
calves, as detailed in Materials and Methods of Section 
II. Days were combined into group intervals as indicated 
on the abscissa of each figure. Figure lA. Plasma PTH 
^gg/ml) and bone degradation activity of monocytes (net % 
Ca release) of milk fever cows for 20-day periparturi-
ent period. Figure IB. Plasma calcium (mg/100 ml) and 
calcitriol (pg/ml) concentrations of milk fever animals 
for 20-day periparturient period. 
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fever and on days 1 to 2 post-milk fever, however, a marked signifi­
cant decline in bone degradation activity occurred relative to peak 
activity on days -2 to -1. Monocyte bone-degrading activity during 
onset of milk fever was unresponsive to the significant increases in 
plasma PTH (P < 0.01). The bone-degrading activity did, however, also 
Increase on days 3 to 4 post-milk fever. 
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DISCUSSION 
The present study demonstrates that monocyte-mediated bone 
degradation Increases prepartally with increasing plasma PTH concen­
trations in paretic cows. Our earlier study in Section II demonstrated 
that exogenous PTH resulted in a significant Increase in monocyte-
mediated bone degradation. Bone degradation activity of monocytes, 
however, was not increased on the days of peak plasma PTH concentra­
tions that occurred at onset of milk fever. These results suggest 
that at onset of milk fever, a time that calcium homeostatlc mecha­
nisms are resistant, monocyte-bone degradation activity is also 
unresponsive to the bone calcium mobilizing hormone PTH. This resis­
tance to PTH action suggests that the hypothesized "scavenger-helper" 
role of monocytes in bone resorption proposed by Heersche (7) may be 
resistant to PTH stimulation at the onset of milk fever, and thus 
possibly contributes to the resulting hypocalcemia and paresis. The 
role of the monocyte in bone resorption must be established firmly 
with further study, though, before this hypothesis Is accepted. 
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SECTION IV. 
PROLIFERATION OF LYMPHOCYTES AND BONE-DEGRADING ACTIVITY 
OF MONOCYTES FROM COWS WITH EDTA-INDUCED HYPOCALCEMIA 
102 
INTRODUCTION 
We evaluated the effect of hypocalcemia induced by EDTA infusion 
on proliferation in mitogen-induced lymphocytes and on monocyte-
mediated bone degradation. EDTA-induced hypocalcemia was used as a 
model of milk fever to evaluate mitogen-induced lymphocyte response 
and monocyte bone degradation activity. Several previous studies have 
used EDTA as a chelating agent of calcium to experimentally induce 
hypocalcemia in cattle (1-3). 
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MATERIALS AND METHODS 
Ethylene Diaminetetraacetate (EDTA) Infusion 
Procedure for EDTA infusion was a modification of methodology of 
Ramberg al. (3). Six Jersey heifers weighing between 250 and 320 
kg were maintained in individual stanchions and fed a diet that met 
NRC requirements for mineral content and caloric intake (4). Teflon 
catheter was placed in one external jugular vein under local lidocaine 
anesthesia. Cows were infused intravenously and constantly for 36 hr 
with disodium EDTA (5 g/hr) sufficient to chelate 541 mEq Ca/hr. An 
additional 12-hr infusion of 0.9% NaCl solution completed the infusion 
protocol. Plasma samples and PBM samples for monocyte isolation and 
bone degradation assay, and for DNA synthesis in mitogen-induced 
lymphocytes were obtained at regular intervals in pre-treatment, 
treatment, and post-treatment phases by jugular venipuncture on the 
side opposite the catheter infusion. 
Assay of Monocyte Bone Degradation 
Monocytes were isolated and evaluated for bone degradation 
activity as detailed in Materials and Methods of Section II. 
Assay of DNA Synthesis in Mitogen-induced PBM 
PBM were isolated and cultured for evaluation of mitogen-induced 
DNA synthesis as described in Materials and Methods of Section II. 
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RESULTS 
Monocyte-mediated bone degradation did change during EDTA infusion 
relative to pre-EDTA values (data not shown). 
PBM DNA synthesis, in response to PHA, ConA, or PWM, were also 
unchanged relative to pre-EDTA values (data not shown). 
Plasma calcitriol concentrations are shown in Table 1. Calcitriol 
concentrations during the two pre-treatment days did not exceed 13 
pg/ml. Infusion of EDTA caused an increase in calcitriol concentra­
tion to 28.6 ± 4.0 pg/ml. Cessation of infusion protocol caused 
calcitriol concentrations to return to pre-EDTA infusion concentra­
tions. 
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Table 1. Plasma calcitriol concentrations during 36-hr 
EDTA infusions in 5 Jersey heifers 
Treatment day Plasma calcitriol (pg/ml) 
Pre-1 12.8 ± 3.0 
Pre-2 6.9 ± 1.0 
1 28.6 ± 4.0 
2 17.7 ± 4.0 
3 
* 
N.D. 
4 6.2 ± 0.4 
Not determined. 
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DISCUSSION 
No change in DNA synthesis proliferation of PBM or activity of 
monocyte-mediated bone degradation was observed during EDTA infusion 
relative to pre-EDTA values. Plasma calcium was not evaluated, but 
the observation of increased plasma calcitriol concentrations suggests 
that hypocalcemia was induced (5), but not to the degree evident in 
milk fever animals (see Fig. IB of Milk Fever study). This experiment, 
therefore, probably did not induce sufficient hypocalcemia to induce 
plasma PTH and calcitriol concentration increases sufficient to affect 
proliferation of mitogen-induced PBM and/or rate of monocyte-mediated 
bone degradation as demonstrated in PTH and calcitriol administration 
studies (see Section II). 
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SECTION V. 
EFFECT OF 24-FLUORO-l,25-DIHYDROXYVITAMIN D3 
ON PROLIFERATION IN MITOGEN-INDUCED PBM 
109 
INTRODUCTION 
24-Fluoro-l,25-dlhydroxyvitamln Dg [24F-1,25-(0H)2D3] is a 
fluorlnated analogue of 1,25-(0H)2D3 that is similar to 1,25-(0H)2D3 
in its hypercalcemia potency (1). This study was designed to evaluate 
the effect of 24F-1,25-(0H)2D3 administration on in vitro prolifera-
tion of mitogen-induced PBM. 
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MATERIALS AND METHODS 
24-F-l,25-DihydroxyviCamln Dg Implant 
Three Jersey heifers weighing between 250 and 320 kg were given 
subcutaneous implants of 24-F-l,25-(0H)2D3 pellets (0.5 mg/pellet) 
(Innovative Research of America, Gaithersburg, MD) in the paralumbar 
fossa under local anesthesia with lidocaine. Three control heifers 
were given implants of pellets containing only carrier (choles-
terolrmethyl cellulose:a-lactose). Plasma and PBM pretreatment, 
treatment, and post-treatment samples were obtained. 
Assay of DNA Synthesis in 
Mitogen-Induced PBM 
PBM were isolated and cultured for assay of mitogen-induced DNA 
synthesis as described in Materials and Methods of Section II. 
Plasma 24-F-l,25-(0H)2D3 and Calcium Concentrations 
Plasma calcium and 24-F-l,25-(OH)2D3 concentrations were evaluated 
as described in Materials and Methods of Section II. The method of 
Reinhardt et (2) was modified for assay of both 1,25-(0H)2D3 and 
24-F-l,25-(OH)2D3 in plasma. 24-F-l,25-Dlhydroxyvitamin D3 and 
1,25-(0H)2D3 comigrated on C18 Sep-Pak silica columns. Separation was 
achieved by subjecting the dihydroxjrvitamin D metabolite fraction from 
the initial C18 Sep-Pak column to high-performance liquid chroma­
tography (HPLC) on a Zorbax Sil column (0.45 x 25 cm, Dupont) devel­
oped in 3:97 (v;v) isopropanol:methylene chloride. Once separated, 
concentrations of both sterols were determined by using a radioreceptor 
Ill 
assay (2). Recovery estimates for 1,25-(0H)2D3 were used to estimate 
recovery of 24-F-l,25-(0H)2D3. 
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RESULTS 
Plasma 24-F-l,25-(0H)2D3 concentrations are shown in Table 1. 
24-F-1,25-(0H)2D3 concentrations peaked at 450-500 pg/ml on days 1-2 
and then remained at about 150 pg/ml for the next 11 days. 
Results of PHA-, ConA-, and PWM-induced lymphocytes proliferation 
from treated and control cows are shown in Fig. 1. No changes in 
proliferation in PHA- or ConA-induced PBM was evident in 24-F-
1,25-(0H)2D3-treated cows. Proliferation of PWM-induced PBM seemed 
inhibited in the 24-F-l,25-(OH)2D3 treatment group, but large standard 
errors caused a lack of significant treatment effects (P > 0.05). 
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Table 1. Plasma calcium and 24-F-l,25-(OH)2^3 concentrations during 
pretreatment period and during implant of pellet containing 
24-F-l,25-(OH)2D3 
Treatment Plasma calcium Plasma 24-F-l,25-(0H)2D3 
day (mg/100 ml) (pg/ml) 
Pre-1 9.2 ± 0.3 14.7 + 0.2 
Pre-2 9.4 + 0.2 14.8 ± 3.0 
1 10.8 + 0.6 413 + 52 
2 11.8 + 0.6 453 + 95 
3 11.2 + 0.7 215 + 43 
4 11.1 + 1.0 206 + 66 
5 11.2 + 0.5 191 + 35 
6 11.5 + 0.6 189 ± 36 
7 12.3 ± 0.5 208 ± 44 
8 12.4 + 0.3 213 + 66 
9 11.9 + 0.3 154 ± 45 
10 12.3 + 0.4 139 + 47 
11 11.5 + 1.3 147 + 75 
12 11.4 + 0.6 99 + 30 
13 12.0 + 0.5 79 + 24 
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Figure 1. Effect of 24-F-l,25-(0H)2D3 administration on in vitro 
proliferation in mitogen-induced PBM. Pellets containing 
24-F-l,25-(0H)2D3 (0.5 mg/pellet) (Innovative Research of 
America, Gaithersburg, MD) were implanted in the subcu­
taneous region of the paralumbar fossa under local anes­
thesia in 3 Jersey cows. Pellets containing carrier alone 
were implanted in 3 control cows. PBM were isolated 
and cultured as described in Methods section of Section II. 
Results are expressed as mean ± S.E.M. [®H]-thymidine 
incorporation (cpm). All assays were done in triplicate. 
The 24-F-1,25-(0H)2D3 pellet implant did not change rate of 
proliferation in mitogen-induced PBM. The experiment may have been 
hampered by the low number of cows per group (n = 3) and the wide 
range of plasma 24-F-l,25-(OH)2D3 concentrations during the experiment. 
It is interesting to note, though, that proliferation in PHA- and 
ConA-induced PBM was not affected by increased plasma 24-F-
1,25-(0H)2D3. This is in marked contrast to l,25-(OH)2D3-induced 
inhibition of vitro DNA synthesis in PHA- and ConA-induced 
lymphocytes demonstrated in earlier studies (3, 4). 
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SUMMARY AND DISCUSSION 
Calcitriol is an Inmunoregulatory steroid hormone that suppresses 
IL-2 production and inhibits proliferation in mitogen-Induced lympho­
cytes. In Section I of this dissertation, the effects of calcitriol 
on in vitro proliferation in bovine PBM was evaluated. Calcitriol 
Inhibited DNA synthesis in PHA- and PWM-induced PBM, but the effect on 
ConA-stimulated PBM was dependent on the initial rates of DNA synthe­
sis. PBM from cows with low proliferative response to ConA were 
stimulated significantly by calcitriol, whereas PBM from cows with 
high proliferative responses were unaffected by calcitriol addition. 
Cells with low initial proliferative response to ConA (low-density 
nonadherent cells) with increasing monocyte additions resulted in 
significant enhancement of DNA synthesis in the presence of cal­
citriol. Cells with high initial proliferative response to ConA 
(high-density nonadherent cells) were inhibited in the presence of 
calcitriol at all monocyte additions, but successive increases in 
relative monocyte additions significantly attenuated the calcitriol-
induced inhibition of DNA synthesis. These studies suggest that the 
calcitriol-induced enhancement of ConA-stimulated lymphocytes is 
mediated on the monocyte, possibly by increased Class II MHC molecule 
expression and/or increased IL-1 synthesis by the monocyte. In Sec­
tion II, the effects of in vivo administration of calcitriol on sub­
sequent vitro proliferation in mitogen-induced PBM were examined. 
In vivo administration of calcitriol resulted in enhancement of in 
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vitro proliferation in PHA- and ConA-induced PBM and inhibition of 
proliferation in PWM-induced PBM relative to pre-calcitriol values. 
These studies of ^  vivo administration of calcitriol also suggest 
that the monocyte mediates the enhanced ConA-induced DNA synthesis 
because the monocyte, and not the T and B lymphocyte, constitutively 
expresses the calcitriol receptor during the calcitriol treatment . 
This research project also examined the effects of the bone 
calcium mobilizing hormones, PTH and calcitriol, on monocyte-mediated 
bone degradation. Monocytes degrade devitalized bone and are found in 
areas of osteoclast bone resorption and in areas of osteolysis associ­
ated with chronic inflammation, such as periodontitis and rheumatoid 
arthritis. The monocyte has, therefore, been proposed as playing a 
role in the bone resorption process distinct from the osteoblast. 
In Section II of this dissertation, I have demonstrated that PTH 
administration significantly increased monocyte-mediated bone degrada­
tion, whereas calcitriol administration had no effect. PTH adminis­
tration also resulted in enhanced monocyte production of H2O2 on the 
same day as peak monocyte-mediated bone degradation. This relation­
ship suggests that PTH induces an inflammatory-type mechanism during 
the increase in monocyte-mediated bone degradation. 
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